TW464509B - A pharmaceutical composition for ameliorating a cellulite condition - Google Patents

A pharmaceutical composition for ameliorating a cellulite condition Download PDF

Info

Publication number
TW464509B
TW464509B TW84108866A TW84108866A TW464509B TW 464509 B TW464509 B TW 464509B TW 84108866 A TW84108866 A TW 84108866A TW 84108866 A TW84108866 A TW 84108866A TW 464509 B TW464509 B TW 464509B
Authority
TW
Taiwan
Prior art keywords
tewl
sebum
skin
treatment
barrier
Prior art date
Application number
TW84108866A
Other languages
Chinese (zh)
Inventor
Walter P Smith
Original Assignee
Mary Kay Cosmetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/296,513 external-priority patent/US5587396A/en
Application filed by Mary Kay Cosmetics Inc filed Critical Mary Kay Cosmetics Inc
Application granted granted Critical
Publication of TW464509B publication Critical patent/TW464509B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365Hydroxycarboxylic acids; Ketocarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/671Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New topically applied treatments for cellulite are shown by comparative data to effect structural improvements in cellulite-afflicted thigh area tissues including skin-thickening, thigh-firming and thigh-reduction. The disclosed treatments disrupt the skin's water barrier and elevate trans-epidermal water loss (TEWL) for extended periods of weeks or months and include methods of mechanical or solvent action, for example, tape stripping, or acetone washes. Preferred treatments use creams with active ingredients such as lactic acid to elevate TEWL, a retinoid, preferably vitamin A palmitate to disrupt barrier rebuilding and prolong elevation of TEWL levels, and a cerebroside to inhibit lipid synthesis and intensify the TEWL elevation. Diuretics, for immediate esthetic improvements, anti-irritants and anti-oxidants for irritation control are optional ingredients.

Description

A7 B7. 經步-部中央標準局員J-消费合作社印取 464509 五、發明説明(i ) 本發明係有關局部施用的皮脂粒治療,包括組成物及 方法,其長期使用時,如每天施用而達數個月之久,可產 生皮脂粒狀況之結構性改善。皮脂粒一詞是指在皮膚下大 量脂肪細胞不正常的聚集|而造成皮膚表面的難看之局部 之視覺不連續性。 皮脂粒是Nicole Ronsard於1970年代創造的名詞(見 Webster's New Universal Unabridged Dictionary,第 二版,Dorset Baber i983 )是於描述非正常脂肪塊狀之 不正常的皮下蓄積而造成皮膚正常之平滑曲線之不雅觀之 阻隔之廣泛現象。 生理上而言,皮脂粒是因身體易發生脂肪蓄積部位的 微循環之退化。嚴重的皮脂粒之特徵爲皮下血管的退化, 血流不良,皮膚表皮及真皮層之變薄,在皮下區域由蛋白 質包圍之脂肪物質之硬塊之出現,及體液之蓄積之貯存。 結果造成皮膚“橘皮”般的外觀。 皮脂粒最常在大腿,臀部及上臂造成問題,較少在外 肢,背部,軀幹及胴體中央,及在臉,頸,手及足上通常 不明顯。皮脂粒通常和肥胖有關,但也出現在正常或近乎 正常體重的個人的皮膚上。在女性比在男性上較常見,亦較 在白種人比在較深膚色的個人身上較常出現。 因嚴重損害個人的外觀,皮膚粒具有深遠的心理影響 ,傷害到受影響個人的自尊及不利於青年男女的健康心理 發展。因此,非常需要有效的皮脂粒治療方法。 已知治療皮脂粒的方法包括局部的機械作用,局部施 本紙浪尺度通用中囷國家標率(ΓΝ5 ) Λ4規格(210X297公漦) (請先閱讀背面之注項再填湾本頁)A7 B7. Step-Ministry of Central Standards Bureau J-Consumer Cooperative Printed 464509 V. Description of the Invention (i) The present invention relates to the topical application of sebum granules, including the composition and method. For long-term use, such as daily application and For several months, a structural improvement in the condition of sebum particles can occur. The term sebum granules refers to the abnormal accumulation of a large number of fat cells under the skin, which results in unsightly local visual discontinuities on the skin surface. Sebum is a term coined by Nicole Ronsard in the 1970s (see Webster's New Universal Unabridged Dictionary, 2nd edition, Dorset Baber i983). It is used to describe the abnormal smooth accumulation of abnormal fat masses and the smooth curve of the skin. Extensive phenomena of estrangement. Physiologically, sebaceous granules are degraded by microcirculation in the body where fat accumulation occurs. Severe sebaceous granules are characterized by the degradation of subcutaneous blood vessels, poor blood flow, thinning of the epidermis and dermis of the skin, the appearance of hard masses of fatty substances surrounded by protein in the subcutaneous area, and the storage and accumulation of body fluids. The result is an "orange peel" -like appearance on the skin. Sebum particles most often cause problems in the thighs, buttocks, and upper arms, and are less common in the extremities, back, trunk, and center of the corpus callosum, as well as on the face, neck, hands, and feet. Sebum particles are often associated with obesity, but they also appear on the skin of individuals of normal or near-normal weight. It is more common in women than in men, and it is more common in Caucasians than in darker-skinned individuals. Due to the serious damage to the appearance of individuals, the skin granules have far-reaching psychological effects, hurt the self-esteem of the affected individuals, and are not conducive to the healthy psychological development of young men and women. Therefore, there is a great need for effective treatment of sebum particles. Known methods for treating sebum granules include local mechanical action, local application of paper waves, general Chinese standard (ΓΝ5), Λ4 size (210X297 cm), (please read the note on the back, and then fill in this page)

*1T ^ 464509 Α7 Β7 五、發明説明() 用化學藥劑,運動,飲食的調整,及這些治療的組合。一 種有效的治療是结合飲食及蓮動,積極地維持一段很長的 時間。許多人尋求較容易的治療方法。由述於此的臨床試 驗證明,已知簡易施用的局部治療方法只提供表面的功效 及不能明顯地改善結構上之缺陷。* 1T ^ 464509 Α7 Β7 5. Description of the invention () Use of chemical agents, exercise, diet adjustment, and a combination of these treatments. An effective treatment is a combination of diet and lotus movements that is actively maintained for a long time. Many people seek easier treatments. From the clinical trials described here, it is clear that the known simple topical treatment methods only provide surface efficacy and do not significantly improve structural defects.

Stewart之美國專利第4,829,987號傳授一種皮脂粒的 治療方法,其需將礦物溶液浸泡的包裹帶施用在一適當的 身體部位,然後對該部位進行被動式蓮動。該治療方法對 許多人而言是不方便或太麻煩的。 按摩能增進撤循環及剌激脫皮,讓皮虜表面變光滑及 增加血液流動,但只是暫時性的。Henderson的美國專利 第4,0从,922號公布了冶療皮脂粒的一種設施及方法。該 設施包括多重的彈性球,其能施用於受影镨的身體部位。 熱治療亦可剌激微循環及提供短期的功效,但不具長 期的結構上之改善。 經濟部中央標準局員工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 身體乳液,藥劑及乳霜含有據聞之活性生物成分,例 如金鏤梅,金雀花,七葉樹果,Μ類,海水或七葉樹素可 提供短期,輕撤之微循環之剌擻,但至多也只具中度的活 性。 前述的按摩*熱治療及生物配方並未考慮到問題如皮 慮之更新,脂肪代謝,體液蓄積或血管之退化。 利尿劑,(通常較佳是植物性的),促進淋巴液抹出 ,產生良好的短期症狀效果但並未考慮長期皮虜缺陷,脂 肪代謝或血管退化。 本紙張尺度適用中國國家標率(CNS ) Α4規格(210Χ297公釐) 經满部中央標率局肩工消費合作社印製 5 45 0 9 a? __B7 ...................^ 五、發明説明(3 ) 咖啡因I茶葉鹼及其他黃嘌呤類,在高濃度時似乎在 作爲利尿劑及在促進脂肪代謝上有效。氨茶鹼,目前是已Stewart, U.S. Patent No. 4,829,987 teaches a method for treating sebum granules in which a mineral solution-soaked wrapping tape is applied to an appropriate body part, and then the part is passively moved. This treatment is inconvenient or too cumbersome for many people. Massage can improve withdrawal and stimulate peeling, smooth the skin surface and increase blood flow, but only temporarily. U.S. Patent No. 4,0,922 from Henderson discloses a facility and method for treating sebum granules. The facility includes multiple elastic balls that can be applied to the affected body parts. Heat therapy can also stimulate microcirculation and provide short-term benefits, but without long-term structural improvements. Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs (please read the precautions on the back before filling out this page) Body lotions, medicaments and creams contain rumored active biological ingredients, such as golden gooseberry, gorse, horse chestnut, class M, Seawater or aesculin can provide short-term, lightly withdrawn microcirculation, but at most it is only moderately active. The aforementioned massages, heat treatments and biological formulas do not take into account issues such as renewal of skin concerns, fat metabolism, accumulation of body fluids or degradation of blood vessels. Diuretics, which are usually plant-based, promote lymphatic exudation and produce good short-term symptoms without taking into account long-term skin defects, fat metabolism or vascular degradation. This paper scale is applicable to China National Standards (CNS) A4 specifications (210 × 297 mm) printed by the Central Standards Bureau Shoulder Workers Consumer Cooperatives 5 45 0 9 a? __B7 ............ ....... ^ V. Description of the invention (3) Caffeine I, theophylline and other xanthines, appear to be effective as diuretics and to promote fat metabolism at high concentrations. Aminophylline is currently

I i 知的大腿部乳霜或大腿平滑乳霜之受歡迎的活性成分,似 乎在作爲促進淋巴液排出之強利尿劑上有效,但據報具有 明顯的毒性副作用(見Merck Index第11版,Merck & Co. Inc. 1989專題論文第477號)。這些藥劑並未考慮皮膚及 血管的結構性缺陷。A popular active ingredient known as thigh cream or thigh smoothing cream appears to be effective as a strong diuretic to promote lymphatic drainage, but has been reported to have significant toxic side effects (see Merck Index, 11th Edition) , Merck & Co. Inc. 1989 Monograph No. 477). These agents do not take into account structural defects in the skin and blood vessels.

Trebosc等人的美國專利第5,030,451號敘述了包含改 良的咖啡因衍生物作爲活性劑之一些化粧組成物。依據 Trebosc等人之第9欄第15-20行,該公開的配方具有 “良好及長效的‘分解脂肪之性質’及因而證明在瘦 身計畫及治療皮脂粒上非常有效。" 然而,並未報導有效的數據。在第1欄第61-65行> Trebosc等人傳授了皮下穿透之較快的速率而確認了這些 藥劑在治療皮脂粒上的優越性。U.S. Patent No. 5,030,451 to Trebosc et al. Describes some cosmetic compositions containing an improved caffeine derivative as an active agent. According to Trebosc et al., Column 9, lines 15-20, the disclosed formula has "good and long-lasting 'fat-breaking properties'" and thus has proven very effective in slimming programs and treating sebum particles. &Quot; However, No valid data have been reported. In column 1, lines 61-65 > Trebosc et al. Taught the faster rate of subcutaneous penetration and confirmed the superiority of these agents in treating sebum particles.

Mausner美國專利第5,21 5,759號參考了使用甲基矽烷 醇茶葉鹼醋酸鹽藻朊酸鹽及甲基矽烷醇甘露糖醛酸鹽供作 防皮脂粒之活動。缺乏說明性之公開,這類物質作用被假 設是等於利尿劑。 推銷刺激物組成物(含咖啡因,氨茶鹼或相關的藥劑 作爲活性組成成分)給消費者用於治療皮脂粒之一個缺點 是用藥方面的問題將阻止其被包括於藥局即可銷售之化粧 品組成物。長期的重複使用也許會引發有害之副作用,而 政府的管制規定會限制市場行銷性。另一個缺點是這類藥 _____ _ 6" . _ 本紙張尺度適用中國國家標坪_ ( CNS ) Μ規格(2ΙΟΧ:297公漦} (請先閲讀背面之注意事項再填寫本頁) ,1Τ 4 5 45 0 9 A7 B7Mausner U.S. Patent No. 5,21 5,759 refers to the use of methylsilanol theophylline acetate alginate and methylsilanol mannuronic acid for the activity of preventing sebum granules. Without descriptive disclosure, the effects of such substances are assumed to be equal to diuretics. One disadvantage of marketing stimulant compositions (containing caffeine, aminophylline or related agents as active ingredients) for the treatment of sebum granules is that medication problems will prevent them from being included in pharmacies for sale Cosmetic composition. Prolonged reuse may cause harmful side effects, and government regulations may limit marketing. Another disadvantage is that this kind of medicine _____ _ 6 ". _ This paper size is applicable to Chinese national standard _ (CNS) M specifications (2ΙΟχ: 297 g 漦) (Please read the precautions on the back before filling this page), 1Τ 4 5 45 0 9 A7 B7

Llti 經淖部肀央栋準局員工消費合作社印聚 五、發明説明( 劑未考慮皮膚及血管缺陷之結構問題。 磨砂顆粒機械作用,磨去治療的外層,平滑治療表面 t t 及刺激治療更新,但未能促進淋巴液排出,長期的微循環 退化或脂肪代謝。磨砂顆粒^硬的顆粒,一般爲懸浮乳霜 或膠,其在治療上磨擦或按摩而達到機械剝落的作用。該 顆粒通常是聚乙烯球,然而天然粒子如壓碎的桃或杏核亦 曾被使用。這些產品進一歩的缺點是很難控制過敏問題。 局部施用的視黃質,例如Kligman之美國專利第 5,051 ,449號,能有限度地改善皮脂粒。Kligman公布了在 超過6個月局部施用視黃酸配方後,和一未指名之非藥用 乳霜之比較功效之定性報告。所述的功效包括皮膚增厚, 新血管數目之增加,及使用捏挾測試(第6欄,第50-61 行)之可觀察到之中度至明顯之改善。因未提供任何定量 數據,因而習知技藝者無法判定Kligman之皮脂粒治療之 教導之價値。 許多人希望及預期皮脂粒治療方法在6個月治療之後 比中度改善更具功效。必須限制所施用的視黃酸濃度以避 免過敏(見Kligman第2欄,第59-60行),因而無法藉由 增加劑量而達到足夠的功效•視黃酸治療方法並未提供對 皮脂粒令人滿意的長期治療,及需要更有效的局部施用的 治療方法。相反於Kligman之未具根據之歸納,我在定量 臨床硏究發現在每天治療達3個月後,視黃酸並未造成明 顯的皮虜增厚作用。因此,需要一種容易施用的皮脂治療 方法,而其能在合理的時間內提供結構性改善。 本纸张尺度適州中國囤家椟净.((::呢)/\4規格(210>:297公麓) (請先閲请背面之注意事項再填寫本頁)Llti Department of Economics and Social Affairs, Consumer Affairs Cooperative of the Central Bureau of the People's Republic of China, Printing Co., Ltd. V. Invention Description (The agent does not take into account the structural problems of skin and vascular defects. Scrub particles act mechanically, remove the outer layer of treatment, smoothen the treatment surface, and stimulate treatment updates. However, it fails to promote lymphatic drainage, long-term microcirculation degradation or fat metabolism. Scrub particles are hard particles, usually suspended creams or gels, which are rubbed or massaged to achieve mechanical exfoliation. The particles are usually Polyethylene balls, however, natural particles such as crushed peaches or apricot kernels have also been used. The disadvantage of these products is that it is difficult to control allergies. Topical retinoids, such as US Patent No. 5,051,449 to Kligman It can improve sebaceous granules to a limited extent. Kligman has published a qualitative report comparing the efficacy of a topical retinoic acid formula with an unnamed non-medical cream after more than 6 months. The efficacy includes skin thickening , An increase in the number of new blood vessels, and an observed moderate to significant improvement using the pinch test (column 6, lines 50-61). Nothing was provided Quantitative data, so skilled artisans cannot determine the value of Kligman's sebum treatment. Many people expect and expect sebum treatment to be more effective than moderate improvement after 6 months of treatment. Retinoids must be limited Acid concentration to avoid allergies (see column 2 of Kligman, lines 59-60) and therefore cannot achieve sufficient efficacy by increasing the dosage • The retinoic acid treatment method does not provide a satisfactory long-term treatment of sebum particles, and A more effective topical treatment is needed. Contrary to Kligman's unfounded induction, my quantitative clinical research found that after 3 months of daily treatment, retinoic acid did not cause significant skin thickening. Therefore, there is a need for an easy-to-apply sebum treatment that can provide structural improvement within a reasonable time. This paper is scaled by Shizhou, China. ((::?) / \ 4 size (210 >: 297) Gonglu) (Please read the notes on the back before filling this page)

,1T A7 B7 J6 45 Ο 9 五、發明説明( 本發明,如所申請專利,是要提供一種治療方法。其 解決提供比以前所得方法更具效力之可對消費者行銷之容 易施用的局部皮脂粒治療方法之問題,及其能在合理時間 內造成明顯的結構性改善。本發明也解決了提供當持續長 期使用時能產生漸進性,結構性改善的局部性皮脂粒治療 方法之問題,較佳的實施例促進身體受皮脂粒影響部位的 皮膚之明顯增厚及增進組織之結實,減少大腿腿圍,及增 加微循環血流。 本發明藉由提供皮脂粒治療方法而解決上述問題,該 方法在受皮脂粒影響的組織破壞該部位皮膚的水障壁特性 一段長時間使足以激發治療的更新及血管之再生而達到增 強之功效。 長期的破壞皮膚障壁是有困難的。當然地,該破壞方 法不能強至傷害皮膚之敏感的真皮層,或造成疼痛或顯著 的過敏。但爲得本發明之功效,該治療應提供持久的破壞 障壁的作用,而非暫時性的效果。因爲障壁的正常作用對 生存是必要的,破壞該障壁會引起自然的反應而快速修補 該障壁。更詳細地,在延長治療期間之數週內,如8週或 更長,障壁作用要持續被破壞 穿透表皮的水分損失之增加可用來監測障壁作用。治 療12週後測量TEWL,最後治療之後至少8小時測量,發現 除了視黃質之外的已知的皮脂粒治療方法具有很少的對障 壁作用之持續的影響,有些似乎降低TEWL。視黃酸,一種 脫皮劑,及至少另一種剝落劑,在12週時只顯示TEWL輕微 本紙张尺度適用中國國家標卒((:NS ) Λ4規格UIOX 297公赘) (請先閲讀背面之注意事項再填寫本頁) '1Τ 經滅部中火標準局貝工消f合作社印製 46 45 0 9 Α7 Β7 經濟部中夾標準局員工消費合作杜印製 五、發明説明() 之增加。 儘管這些困難,發現許多治療方法在破壊障壁作用方 面有效*及當長期持續使用時,如每天一次或二次,能在 8週或12週產生TEWL明顯之增加。 能用於本發明之障壁破壞方法包括以低分子童非掻性 腊質之皮虜可接受的有機溶劑如丙酮,或以皮#可接受的 表面活性劑如硫酸十二烷基納,而對角質層的脂質結構作 直接的生理一化學破壊。這類方法剝難及除去障壁組成成 分的脂質。然而較佳是使用局部施用的保餐組成物,其以 能被皮着吸收的美學上吸引人*不具臭味之配方如乳霜形 式含有化學活性的障壁破壊組成成分。其他合適的障壁破 壞方法是習知技藝者所知或清楚的。 進一步發現藉由抑制皮®脂質的合成可抑制或控制障 壁的修復,而使得長期8週或12週TEWL之增加能顯箸地加 強。如Proksch等人於 “Barrier Function regulates ep i derma 1 lipid and DNA synthesisw British Jouna1 of Dermatology ( 1993) 128, 473-482所教授,鼠類硏究 顯示障壁作用之破壞會造成表皮活層之游離脂防酸,神經 鞘脂質及膽固醇之合成增加,而導致像壁之修復。 在本發明選擇性實施例中,抑制這類合成Μ降低用於 修復障壁的游離脂肪酸,神經鞘脂質及膽固醇的可取得性 ,例如藉由局部施用腦甙供吸收。其他適合的抑制劑是習 知技藝者所知或清楚的。當皮脂粒治療方法除去或洗去皮 »脂質,脂質合成抑制劑是在和障壁破壞不同的步驟施用 ^^^1· ^^^^1 In i^n ^ (諳先聞讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家橾準(CNS〉A4说格(210X297公釐) 9 464509 Α7 Β7 五、發明説明() 。當障壁破壞是由局部施用活性劑而達成時,脂質合成抑 制劑可包含於該配方中。 此種脂質合成抑制劑之使用可防止水障壁之快速再生 及提供皮脂粒狀況之結構性改善。 同時發現就整値8週的延長的長期皮脂粒治療 而言,穿透表皮的水分損失(Yewl (其可直接測量))是 監測皮脂粒治療功效之很有價值的指棟。以持續基礎逹到 的TEWL增加的程度亦在預測皮脂粒治療功效上有用,因其 功效只在長程使用後,如數遇,更可能地二至六値月或更 長後才變得明顯。藉由測量多種皮脂粒治療的TEWL,而我 相信其目前未曾被用來評估皮脂粒治療的功效,發現已知 的治療方法只提供TEWL暫時及短暫的增加,及沒有一個提 供數週或數月的TEWL持續性增加。發現藉由引發明顙及持 鳙的TEWL之增加,能達到皮脂粒狀況之有利的結構性改善 0 經濟部中央標準局負工消費合作社印製 (請先閱讀背面之注意事項再填寫本頁) 此外,藉由監測各種冶療方法所造成的TEWL程度,而 能設計一種新的皮脂粒治療方法,其能在通常長達8週, 12週或更長的治療期間維持長期或持續增加的TEWL。較佳 地在8週或更長的期Μ ^此新的治療方法至少提昇T£WL 100%。在治療期間實質上200%或300%之更高的增加是 有利的。 在一方面,本發明提供改善皮脂粒狀況的方法,其包 括受影繼的皮慮區持鏞施用局部的水障壁破壊治療,Μ產 生8週至逹成所要的皮脂粒改善之期間之長期增加的穿透 本紙張尺度適用中國國家標準(CNS )Α4规格(210 X 297公釐) 10 A7 B7 五 經濟部中央棉準局負工消贽合作社印Μ 464509 、發明说明(8 ) 皮膚水分損失。一般該治療是每天施用一或二次。 許多新的皮脂粒治療方法包括皮膚的各種局部機械治療,1T A7 B7 J6 45 Ο 9 5. Description of the invention (The present invention, as applied for a patent, is to provide a treatment method. It solves the problem of providing easy-to-apply topical sebum that can be marketed to consumers more effective than previous methods. The problem of the granule treatment method, and it can cause obvious structural improvement in a reasonable time. The present invention also solves the problem of providing a local sebum granule treatment method that can produce gradual and structural improvement when continued long-term use. The preferred embodiment promotes the obvious thickening of the skin of the body affected by sebaceous particles and the strengthening of tissues, reduces the thigh and thigh circumference, and increases the microcirculation blood flow. The present invention solves the above problems by providing a sebum particle treatment method, Methods The tissues affected by sebaceous granules destroy the water barrier properties of the skin in this area for a long time, which is enough to stimulate the renewal of the treatment and the regeneration of blood vessels to achieve enhanced effects. It is difficult to destroy the skin barrier for a long time. The method must not be so strong as to damage the sensitive dermis of the skin or cause pain or significant allergies. Effectiveness of the invention, the treatment should provide a long-lasting effect of destroying the barrier, not a temporary effect. Because the normal function of the barrier is necessary for survival, destroying the barrier will cause a natural response to quickly repair the barrier. In more detail In the weeks of extended treatment, such as 8 weeks or longer, the barrier effect must be continuously destroyed. The increase in water loss penetrating the epidermis can be used to monitor the barrier effect. TEWL is measured after 12 weeks of treatment and at least 8 hours after the last treatment Measurements found that known sebum granule treatment methods other than retinoids have little sustained effect on the barrier effect, and some seem to reduce TEWL. Retinoids, a peeling agent, and at least another exfoliating agent, in Only show TEWL at 12 weeks. This paper size is applicable to Chinese national standard ((: NS) Λ4 specification UIOX 297). (Please read the precautions on the back before filling this page.) '1Τ Printed by the Industrial Consumers Cooperatives 46 45 0 9 Α7 Β7 Printed by the Consumers ’Cooperative Standards Bureau of the Ministry of Economic Affairs, Du Printing 5. Increasing the number of invention descriptions. Despite these difficulties, the Many treatments are effective in breaking the barrier effect * and when used continuously for a long time, such as once or twice a day, can produce a significant increase in TEWL at 8 or 12 weeks. Barrier destruction methods that can be used in the present invention include low molecular weight The organic solvents acceptable for children's non-sexy waxy skin such as acetone, or skin-acceptable surfactants such as sodium dodecyl sulfate, directly physiologically and chemically break the lipid structure of the stratum corneum. This type of method is difficult to remove and remove the lipids of the barrier constituents. However, it is preferable to use a topically applied meal-preserving composition which is aesthetically attractive that can be absorbed by the skin * non-odorous formula such as cream contains chemical Active barrier rupture composition. Other suitable barrier destruction methods are known or clear to those skilled in the art. It was further discovered that by inhibiting the synthesis of dermal lipids, the repair of the barrier can be inhibited or controlled for 8 or 12 weeks. The increase in TEWL can be significantly enhanced. As Proksch et al. Teach in "Barrier Function regulates ep i derma 1 lipid and DNA synthesisw British Jouna1 of Dermatology (1993) 128, 473-482, rodent research has shown that the destruction of the barrier effect will cause the prevention of free lipid in the active layer of the epidermis. Increased synthesis of acids, sphingomyelin, and cholesterol, leading to repair of the wall. In an alternative embodiment of the present invention, inhibition of such synthesis reduces the availability of free fatty acids, sphingomyelin, and cholesterol for repairing the barrier. For example, by topical application of cerebroside for absorption. Other suitable inhibitors are known or clear to those skilled in the art. When sebum granule treatment methods remove or wash away the skin »lipids, lipid synthesis inhibitors are different from barrier destruction ^^^ 1 · ^^^^ 1 In i ^ n ^ (谙 Please read the precautions on the back before filling this page) This paper size is applicable to China National Standards (CNS> A4 Grid (210X297mm) ) 9 464509 Α7 Β7 V. Description of the invention (). When the barrier destruction is achieved by topical application of an active agent, a lipid synthesis inhibitor may be included in the formulation. Such lipid synthesis inhibits The use of the formulation prevents rapid regeneration of the water barrier and provides structural improvement in the condition of sebum granules. At the same time, it was found that for prolonged long-term sebum granule treatment for 8 weeks, the water loss through the epidermis (Yewl (which can be directly measured )) Is a very valuable indicator for monitoring the efficacy of sebum granules. The extent of TEWL increase on a continuous basis is also useful in predicting the efficacy of sebum granules treatment, because its efficacy is only after long-term use. It becomes apparent after two to six months or longer. By measuring the TEWL of various sebum treatments, I believe it has not been used to evaluate the efficacy of sebum treatments and found that known treatments only provide TEWL temporarily And a brief increase, and none of which provided a continuous increase in TEWL for weeks or months. It was found that by inducing and increasing the increase in TEWL, a favorable structural improvement in sebum status can be achieved. 0 Ministry of Economic Central Standards Printed by the Bureau ’s Consumer Cooperatives (please read the notes on the back before filling this page) In addition, by monitoring the TEWL level caused by various metallurgical treatment methods, Design a new treatment method for sebum granules that can maintain a long-term or continuous increase in TEWL during treatment periods typically up to 8 weeks, 12 weeks, or longer. Preferably, the new period is 8 weeks or longer. Therapeutic methods increase T £ WL by at least 100%. A substantially higher increase of 200% or 300% during the treatment period is advantageous. In one aspect, the invention provides a method for improving the condition of sebaceous granules, which includes the affected skin The local area was treated with local water barrier rupture treatment, and the long-term increase in penetration during the period from 8 weeks to the improvement of the desired sebaceous granules was achieved. This paper applies the Chinese National Standard (CNS) A4 specification (210 X 297 mm). 10 A7 B7 Five Central Ministry of Economic Affairs, Central Cotton Standards Bureau, Consumer Work Co-operative Cooperative, Printing M 464509, Description of Invention (8) Skin moisture loss. The treatment is generally administered once or twice daily. Many new sebum treatments include various local mechanical treatments of the skin,

J 如磨砂,粗化或萃提或溶劑萃取治療,二種治療方法都是劇烈 或急進地施用使能如上述提昇TEWL 100%或更多及維持一段長 時間。然而,較佳的治療方法包括能局部施用的一種化學組成 物,較佳是柔化劑或乳霜形式,及以每天不超過一或二次施用 的頻率而能維持增加的TEWL程度。 淸楚地,須控制本發明之治療方法之急遽性以使其能 在數週或數月之期間被接受,而不致造成嚴重或痛楚的過 敏,變紅’脫皮或過度的不適。然而,許多人可容忍這些 症狀之短期出現。 本發明另一方面提供了一種皮脂粒組成物,其包括能 立即或短期增加TEWL之TEWL增加劑及其作用爲維持增加的 TEWL程度的障壁破壞劑。較佳地,該組成物也包括皮膚脂質 口成抑制劑,以預防水障壁之過早重建及加強該組成物之皮 脂粒治療功效。 本發明此方面之較佳實施例中,該TEWlJf加劑是化粧上 相容的,降低pH値的羥基羧酸,較佳具有剝落劑的性質,及 至少中度可溶於水或氫化醇中使能包含於化粧組成物中。這 類的酸包括α-羥基羧酸,特別是例如乳酸及乙醇酸,及其 他羥基羧酸,如2-羥基本酸,特別是水楊酸。這些酸之有效 性似乎和其能降低皮膚之細胞間液之邱値的能力有關。所使 用的酸及其濃度之選擇是爲了達到所要的TEWL之增加而不造 成過度之過敏。 (請先閱请背面之注意事項再填寫本頁) 訂 -11 - 46 45 0 9 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明() 較佳的障壁修復抑制劑是視黃醴或其衍生物,特佳的 視黃酸是雒他命A棕櫊酸鹽。涉及體内測試對各種皮脂粒 治療方法之人體反應之臨床試驗,其細節迷於後,顯示乳 酸和維他命A棕櫊酸鹽之間相當未預期到之有利的交互作 用*其對皮脂粒之長期治療是有利的。 較佳的脂質合成抑制劑是腦甙或富含腦甙的物質。其 他可選擇的組成成分是能剌激血流及除去過多液體的利尿 劑,及能緩和T EWL增加劑或細胞更新剌激劑之副作用之抗 過敏劑。 以化粧或藥用脫皮劑,乳液或滋養配方出售之用作局 部施用的本發明組成物之組成物配方的適合的相對比例及 其施用頻率描述於後。較佳的化粧配方是適合消費者每天 按摩,或只是塗抹或磨擦 > 的乳霜。其他可用於達成本發 明優點的這類定量指標,是習知技藝者所知的。 Μ下的實驗數據顯示,依據本發明的組成物提供治療 皮脂粒之新程度的功效,及能夠顯箸增加皮虜厚度*增加 血流及促進血管生成。如所報導,曾仔細地定量了此類及 其他產品之功效。 皮脂粒區具有不良的血流。報導於後之本發明實施例 之臨床試驗顯示立即改善血潦4-8小時,而長期使用者 為8 -16週,經由血管生成作用而長期改善血流,因此減 少了受皮脂粒影銎的組織之缺陷。此外,在8至16遇治療 後在皮下區增加了表皮一真皮皮*區之皮虜厚度及密度。 更重要的,組織密度之增加顯示這是一正面之效果及霧k (請先閱讀背面之注意事項再瑣寫本頁) -9 本紙張尺度適用中國國家梂準(CNS ) Λ4規格(2丨OX297公釐) 4 6 45 0 9 經濟部中央標準局員工消費合作杜印製 A7 ____B7_五、發明説明() ,及表皮較結實及具彈性*及皮下區具有較少的脂肪及將 降低外部液體。這些都是歸因於本發明治療方法的結構性 改善。 皮脂粒之發生通常可Μ三或四階段的過程敘述。在此 ,為了提供說明模式而不限制本發明之範畴,皮脂粒之發 生將被視作具有下列性質之三階段過程: 第一階段在受影镟區域的血管開姶舒張及漏。在此階段 ,在表面造成的影響很輕撒,而修復血管完整性及除去過 多液體的治療方法可為非常有效。雷射Doppler檢驗可發 現不正常的血流而生檢法可顯示次表層的缺陷。 第二階段因脂肪及細胞大小之急遽增加而廉重地擾亂了 脂肪細胞新陳代謝作用。雷呑入之脂肪細睢附在一起而形 成脂肪小球。血管的完整性進一步受損,亦可見真皮及表 皮之受影罌。這類影埵之例子如表皮薄化*真皮血管分布 之不良,因不良的撤循環使皮膚表面變成粗躁及灰色及造 成表面之不均一性,即開姶可見“橘皮表S”之形成。 第三階段段在第三階段,觀察到持續的撤血管分布的破 壊,及持繙的液體蓄積 > 脂肪合成之增加及脂肪新陳代謝 速率之降低。脂舫細胞被吞入,財在一起及被由不正常的 隳原質形成的膠原質殼所包圍。這些明顯的小瘤之直徑可 爲數公分,在皮虜表面是明顯的,及可能非常痛。該膠原 質包圍的脂肪小瘤重新導向微血管網路及代表了血流減少 的區域。因液體蓄積,脂肪小瘤的存在*及重力的影響, 皮下脂防區是非常組雜零散的。橘皮狀皮虜顯然易見,而 (請先閱讀背面之注意事項再填寫本頁) ,1Τ 本紙張尺度適用中國國家標準(CNS > A4規格(210X297公釐) ,Λ -13 - 464509 A7 B7 經濟部中央樣準局員工消費合作社印製 五、發明説明() 表面之不均一性是明顯的。表皮及真皮變得較薄及較不結 實及組織不良。在皮*表面眼睛即可看出其不正常性,及 對受駸重皮脂粒影逛的大多數人而言是不美觀及難堪的。 數種生物物理方法可用來測量及記錄皮脂粒,例如, 經由雷射Doppl er測血流,經由溫度記錄法,及組纗學評 估,可直接測量結實度及彈性。依治療方法針對的症狀, 可採用各棰技術測定一特定皮脂粒治療方法的功效。也發 展了一些其他技術以增進對此述皮脂粒治療方法及組成物 的臨床轷估。Μ下是這類治療方法的短而非完整的清單: 大腿直徑測量可追踪作用於薄的皮脂粒區域的產物之功 效。對涉及飲食及蓮動的治療方法最有效。這是種不佳, 不1敏及無差別性的方法。 雷射Doppler測量可發現血管分布的破壞,及產生對血 管分布完整性之效果。能容易觀察到因產品而造成的短期 之血管舒張作用。較好的產品所造成的血管生成(血管再 生)效果及血管完整性的長期觀察是可逹成的但較困難, 且需要好的技術專才。 超音波掃瞄是非常有效的技術 > 能測出皮下膪肪,血管 分布及表皮及真皮完整性之改變。能以皮虜趄音波掃瞄之 電腦分析而測量皮虜厚度。超音波掃瞄提供了測量表皮及 真皮厚度之客觀及正確的非侵襲性方法。 溫度記錄法比雷射Doppler更圖表式的方法來顯示血管 之不足。 皮虜結實度及彈性測量整値真皮,表皮及皮下區域之一 (請先閲讀背面之注意事項再填寫本頁)J For scrubs, roughening or extraction or solvent extraction treatments, both treatments are applied violently or aggressively to enable TEWL to be increased by 100% or more as described above and maintained for a long time. However, preferred treatments include a chemical composition that can be applied topically, preferably in the form of a softener or cream, and that maintains an increased level of TEWL at a frequency not exceeding one or two applications per day. Clearly, the urgency of the treatment method of the present invention must be controlled so that it can be accepted over a period of weeks or months without causing severe or painful allergies, redness' peeling or excessive discomfort. However, many people can tolerate the short-term appearance of these symptoms. Another aspect of the present invention provides a sebum granule composition comprising a TEWL increasing agent capable of increasing TEWL immediately or short-term, and a barrier-damaging agent which acts to maintain the increased TEWL level. Preferably, the composition also includes a skin lipid inhibitor, to prevent premature reconstruction of the water barrier and enhance the therapeutic effect of the composition on the sebum particles. In a preferred embodiment of this aspect of the invention, the TEWlJf additive is a cosmetically compatible hydroxycarboxylic acid with a reduced pH, preferably has the properties of a peeling agent, and is at least moderately soluble in water or hydrogenated alcohol Enables inclusion in a cosmetic composition. Such acids include alpha-hydroxycarboxylic acids, especially such as lactic acid and glycolic acid, and other hydroxycarboxylic acids, such as 2-hydroxycarboxylic acid, especially salicylic acid. The effectiveness of these acids seems to be related to their ability to lower the skin's intercellular fluids. The acid used and its concentration are chosen to achieve the desired increase in TEWL without causing excessive hypersensitivity. (Please read the notes on the back before filling this page) Order -11-46 45 0 9 A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention () The best barrier repair inhibitor is retinopathy Gadolinium or its derivatives, particularly preferred retinoic acid is betaine A palmitate. A clinical trial involving in vivo testing of human responses to various sebum granule treatment methods, fascinated by the details, shows a rather unexpected and beneficial interaction between lactic acid and vitamin A palmitate * its long-term effect on sebum granules Treatment is favorable. Preferred lipid synthesis inhibitors are cerebrosides or cerebroside-rich substances. Other optional ingredients are diuretics that stimulate blood flow and remove excess fluid, and anti-allergic agents that alleviate the side effects of T EWL increasers or cell regeneration stimulants. Suitable relative proportions of the composition formulations of the composition of the present invention sold as cosmetic or medicinal peeling agents, emulsions, or nourishing formulations for local application and the frequency of their application are described below. The preferred makeup formula is a cream suitable for consumers to massage daily, or just apply or rub >. Other such quantitative indicators that can be used to achieve the advantages of the invention are known to those skilled in the art. The experimental data under M show that the composition according to the present invention provides a new degree of efficacy in treating sebum particles, and can significantly increase the thickness of skin cells *, increase blood flow and promote angiogenesis. As reported, the efficacy of these and other products has been carefully quantified. Sebum region has poor blood flow. The clinical trials reported in the examples of the present invention show immediate improvement in blood diarrhea for 4-8 hours, compared with 8-16 weeks for long-term users, and long-term improvement of blood flow through angiogenesis, thus reducing the effects of sebum particles. Organizational defects. In addition, the thickness and density of epidermis-dermal skin * regions were increased in the subcutaneous area after 8 to 16 treatments. More importantly, the increase in tissue density shows that this is a positive effect and fog (please read the precautions on the back before writing this page) -9 This paper size applies to China National Standard (CNS) Λ4 specification (2 丨OX297 mm) 4 6 45 0 9 Consumption cooperation between employees of the Central Bureau of Standards, Ministry of Economic Affairs, Du printed A7 ____B7_ V. Description of the invention (), and the epidermis is firmer and more flexible * and the subcutaneous area has less fat and will reduce external liquid. These are due to the structural improvement of the treatment method of the present invention. The occurrence of sebaceous granules can usually be described in three or four stages. Here, in order to provide an explanation mode without limiting the scope of the present invention, the occurrence of sebum granules will be regarded as a three-stage process having the following properties: The first stage is vasodilation, relaxation, and leakage of the blood vessels in the affected area. At this stage, the impact on the surface is light, and treatments that repair vascular integrity and remove excess fluid can be very effective. Laser Doppler tests can detect abnormal blood flow and biopsies can show subsurface defects. The second stage, due to the rapid increase in fat and cell size, disrupts the metabolism of fat cells inexpensively. The fat entrapped by thunder sticks together to form fat globules. The integrity of the blood vessels is further impaired, and the affected papillae of the dermis and epidermis can also be seen. Examples of this type of shadow are thinning of the epidermis and poor distribution of dermal blood vessels. Due to the poor withdrawal cycle, the skin surface becomes rough and gray and the surface is uneven, that is, the formation of "orange peel surface S" can be seen in the opening and closing. . The third stage In the third stage, continuous rupture of the vasculature distribution and perpetual accumulation of fluid > increase in fat synthesis and decrease in fat metabolism rate were observed. Lipid cells are swallowed, stored together, and surrounded by a collagenous shell formed by abnormal peptones. These distinct nodules can be several centimeters in diameter, are visible on the surface of the skin, and can be very painful. This collagenous lipomas are redirected to the microvascular network and represent areas of reduced blood flow. Due to fluid accumulation, the presence of lipomas, and the effects of gravity, the subcutaneous lipid defense zone is very fragmented. The orange peel-like skin is clearly visible, and (please read the precautions on the back before filling this page), 1T This paper size applies to Chinese national standards (CNS > A4 size (210X297 mm), Λ -13-464509 A7 B7 Printed by the Consumer Cooperative of the Central Bureau of Probability of the Ministry of Economic Affairs 5. Description of the invention () The heterogeneity of the surface is obvious. The epidermis and dermis become thinner and less strong and poorly organized. You can see it on the skin * surface It is abnormal and unsightly and embarrassing for most people who are affected by heavy sebum particles. Several biophysical methods can be used to measure and record sebum particles, for example, by measuring blood with a laser Doppler Flow can be directly measured for firmness and elasticity through temperature recording and histological evaluation. According to the symptoms targeted by the treatment method, the effectiveness of a specific sebum particle treatment method can be measured using various techniques. Other technologies have also been developed to Improve clinical evaluation of these sebum granule treatment methods and compositions. Below is a short, but not exhaustive, list of such treatments: Thigh diameter measurements track the area of thin sebum granules The efficacy of the product. It is most effective for the treatment methods involving diet and lotus movement. This is a poor, insensitive and non-differential method. Laser Doppler measurement can detect the damage of blood vessel distribution and produce integrity of blood vessel distribution Effect. It is easy to observe the short-term vasodilation effect caused by the product. The long-term observation of the angiogenesis (angiogenesis) effect and vascular integrity caused by the better product can be formed, but it is more difficult and requires Good technical expertise. Ultrasound scanning is a very effective technique. Can detect changes in subcutaneous fat, blood vessel distribution, and epidermal and dermal integrity. Can analyze skin lesions by computer analysis Thickness. Ultrasound scanning provides an objective and accurate non-invasive method for measuring the thickness of epidermis and dermis. Thermography is a more graphical method than laser Doppler to show the lack of blood vessels. Skin firmness and elasticity measurement One of genuine leather, epidermis and subcutaneous area (please read the precautions on the back before filling this page)

、ST 本紙張尺度適用中國國家標车(CNS ) A4規格(2!0X297公釐) 14 - 464509 A7 B7 五、發明説明() 經濟部中央標準局員工消費合作社印装 般健康及完整性。 皮脂粒分级在此所述的皮脂粒分级是代表視凳檢査皮虜 之瘤狀及鬆弛情況及皮虜缺陷及掐皮虜而測試小瘤之結果 之總合的數字。 組織學組銪學(皮虜生檢法之檢査)能顯示如嘐原質及 撣力素合成及新血管生成方面測量之改變,及能記錄結構 之改變。組继學通常是敘述皮脂粒問題的程度及測定一產 品的實際效果的最正確方法,但為侵襲性的及具有其他缺 點。 相片及複製其效果有限。消費者的印象通常是較好的工 具。皮脂粒是“大”的皮虜效應,而複製通常顯示太多細 節。相片很難評估。 發明之較徉奮旃例 本發明的較佳實施例使用方法或物質Μ引發皮着水障 壁功能的喪失,以造成皮虜中實質上開始皮虜修復過程的 因子之釋出。藉由破壊障壁功能,皮*的反應如同受傷時 一般而開始一般性的修復過程,其增加表皮及真皮的新陳 代謝及更新,或血管的生成,該過程是在障壁逋破壊時釋 出的目前仍未界定请楚的皮省訊號之控屬下= 在建立下列報導的數據之過程中的觀察顯示按摩,磨 擦海線(BUFF-PUFF (商檫)),及脫皮顆粒雖然在使用後 可暫時增加TEWL數分鐘或數小時,並不能雒持該效果。自 這些觀察而歸納出長期的TEWL之增加是逹到所要的結構性 改善所必需的。 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS ) A4规格(210X297公釐) 15 464509 經濟部中央標準局員工消費合作杜印製 A7 B7五、發明説明() 類似地》脫皮治療如臉部脫皮(例如,20-30%乳酸 或乙醇酸或相等者)之單次使用或如毎週使用一次之間隔 性重複使用,雖然在治療後增加TEWL數天,但並未達成所 要的皮膚修復及皮脂粒改善的效果。此外,如本發明之觀 念,其缺乏功效是因爲該治療方法未能在長的治療過程中 ,例如長達8週,維持TEWL之增加率。 敘述於下的實驗數據顯示沒有Μ前已知的皮脂粒治療 方法造成障壁作用之持續破壞,及沒有一種經由簡單的局 部,區域性施用於能產生將嚴重受到皮脂粒影辔區域回復 到正常或近似正常狀況之足夠明顯的功效。 TFWL:>潮慑 依據本發明*在接受各種皮脂粒治療方法,包括傅統 的治療方法及其中一些彘依據本發明之新的治療方法*的 個體測量TEWL。同時也進行基礎血流之測量*大睡直徑測 量及皮脂粒之比較性臨床分級,及所引發的過敏。 用SERVD-MED牌的蒸發計來測量TEWL。該儀器包括了 一値水分收集室,其封閉了一皮虜表面區域。該儀器測量 依水分而定的電導,及在達到穩定狀態時讀取TEWL。個體 在溫度約68-7ΓΡ及褶對狼度約下預處理:用於Η 下測試之儀器之靈敏度約為± 10%。 在報導於下的臨床試驗中,方法涉及在局部施用皮脂 粒治療方法之皮霜區域進行TEWL之測量,皮脂粒及其他比 較性局部治療方法是毎天施用二次,而TEWL之測量是在早 上施用前不久進行的。例如,在許多例子*該治療方法約 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度逋用中國國家揉牟(CNS ) Α4規格< 2ί〇Χ297公釐} 16 A7 B7 464509 五、發明説明( 在10 a.m.及6至8 p.ro.施用’而TEWL之測量是在約9 a . m . 進行,約早上施用前之1小時及晚上施用之後至少8小時 ) 或更長。 利用上一段所述方法評估一些技藝中皮脂粒治療方法 在提昇TEWL上之功效。以雷射Doppler測定基礎血流然後評 比較性的等級。此外,以技藝中所知的方法測量大腿結實度 及直徑,而皮膚厚度是以i述的超音波測定。皮膚厚度是測 定表皮一ϋ皮層爲第一個數據,也測皮下區域爲第二個數據 在括弧中者。當治療改善皮膚結構時,表皮一真皮層加厚(第 一個數據增加)而柔軟的含水的皮下區域因改善的微循環除 去過多的液體而減少(在括弧中之負的數據)。皮脂粒的嚴 重性是以比較性的等級而作臨床上之分級*過敏作用亦如此。 在下列的臨床實驗中,依據下列的等級而決定皮脂粒 的分級: 0 無表面之凹陷不平或缺陷。 1 在表面眼睛可見之不連續的陷下部分或凹洞。 2 眼睛可見之較大的線狀細溝(在表面之凹陷)。 3 多重眼睛可見及明顯的細溝或凹陷部分,不均 勻膚色,顏色變異。 4 如第3級而具有明顯的表面下之小瘤。 過敏是以Minolta Chroma計,Minolta Camera Co,, ST This paper size is applicable to China National Standard Vehicle (CNS) A4 specification (2! 0X297 mm) 14-464509 A7 B7 V. Description of the invention () Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economy General health and integrity. Sebum Grain Classification The sebum granule classification described here is a number representing the total result of the visual inspection of the tumors and flaccidity of the skin and examination of skin defects and skin lesions. Histology and histology (examination of the skin biopsy method) can show changes in measurements such as the synthesis of protoplasts and elements, and neoangiogenesis, as well as the ability to record structural changes. Group studies are usually the most accurate way to describe the extent of sebum problems and determine the actual effect of a product, but they are invasive and have other shortcomings. Photos and copying have limited effects. Consumers' impressions are usually better tools. Sebum granules are the "big" skin effect, and replication often shows too much detail. Photos are difficult to evaluate. Comparative Examples of the Invention In the preferred embodiment of the present invention, the use of the method or substance M causes the loss of the function of the skin barrier to cause the release of factors in the skin that substantially begin the skin repair process. By breaking the barrier, the skin responds as if it were injured and begins a general repair process, which increases the metabolism and renewal of the epidermis and dermis, or the formation of blood vessels. This process is currently released when the barrier is broken. Undefined, please control the skin province signal = Observations during the establishment of the following reported data show that massage, friction sea line (BUFF-PUFF (商 檫)), and peeling particles may temporarily increase after use TEWL can't hold on to this effect for minutes or hours. From these observations, it is concluded that the long-term increase in TEWL is necessary to achieve the desired structural improvement. (Please read the precautions on the back before filling this page) This paper size is applicable to the Chinese National Standard (CNS) A4 specification (210X297 mm) 15 464509 Employees' cooperation cooperation of the Central Standards Bureau of the Ministry of Economic Affairs, printed A7 B7 5. Description of the invention ( ) Similarly "peeling treatment such as facial peeling (for example, 20-30% lactic acid or glycolic acid or equivalent) single use or intermittent repeated use such as once a week, although TEWL is increased for several days after treatment, but The desired skin repair and sebum particle improvement effects have not been achieved. In addition, as in the concept of the present invention, its lack of efficacy is due to the failure of the treatment method to maintain the TEWL increase rate over a long course of treatment, such as up to 8 weeks. The experimental data described below show that there is no continuous destruction of the barrier effect caused by sebaceous granule treatment methods known before M, and none of which can be applied locally and regionally to restore the severely affected areas of sebum grains to normal or Sufficiently obvious effect to approximate normal conditions. TFWL: > Tide deterrence TEWL is measured by individuals who have received various sebum granule treatment methods, including Fu Tong's treatment method and some of the new treatment methods according to the invention, according to the present invention. At the same time, the measurement of basic blood flow, the measurement of the diameter of large sleep, the comparative clinical classification of sebaceous granules, and the allergies caused. TEWL was measured with a SERVD-MED evaporator. The instrument includes a stack of moisture collection chambers that encloses a skin area on the skin. The instrument measures conductance as a function of moisture and reads TEWL when steady state is reached. Individuals were pretreated at a temperature of about 68-7ΓP and fold-to-wolf degree: the sensitivity of the instrument used for the sub-test was about ± 10%. In the clinical trials reported below, the method involves measuring TEWL in the cream area of the topical application of sebum granules. Sebum granules and other comparative local treatments are administered twice a day, while TEWL is measured in the morning. Performed shortly before application. For example, in many cases * the treatment method is about (please read the precautions on the back before filling this page) This paper size uses China National Rubbing (CNS) Α4 specifications < 2ί〇 × 297 mm} 16 A7 B7 464509 5 2. Description of the invention (at 10 am and 6 to 8 p.ro. administration 'and TEWL measurement is performed at about 9 a.m., about 1 hour before morning application and at least 8 hours after evening application) or longer. Use the method described in the previous paragraph to evaluate the effectiveness of some sebum granule treatments in improving TEWL. Basal blood flow was measured with a laser Doppler and then rated for comparison. In addition, the thigh firmness and diameter were measured by a method known in the art, and the skin thickness was measured by the ultrasonic method described above. The thickness of the skin is determined by measuring the epidermis and cortex as the first data, and also measuring the subcutaneous area as the second data in brackets. When treatment improves the structure of the skin, the epidermal-dermal layer thickens (the first data increases) and the soft, water-containing subcutaneous area decreases due to improved microcirculation except for excess fluid (negative data in parentheses). The severity of sebum granules is clinically graded on a comparative scale * as is the allergic effect. In the following clinical trials, the classification of sebum granules is determined according to the following grades: 0 No surface depressions or defects. 1 Discontinuous depressions or depressions visible on the surface of the eye. 2 Large linear sulcus (dent on the surface) visible to the eyes. 3 Multiple ditches or depressions visible and obvious on multiple eyes, uneven skin tone and color variation. 4 As a grade 3, there are obvious nodules. Allergies are based on Minolta Chroma, Minolta Camera Co,

Ltd.之工業標準方法作皮膚顏色之比較色度測定而評估。 另外記錄其他主觀的施用後感受如刺激,燃燒及皮膚發紅 (請先聞讀背面之注意事項再填寫本頁) 訂 ^ 經 部 中 標 準. Μ} Μ X 消 f 合 作 社 印 464509 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明() ,而該資料納入臨床過敏指檷中,其具有0至5的等级, 0指沒有可識別的或據報的過敏,而5指嚴重的過敏。 習知抟庠脂粒治痗方法夕臨床窗賒 習知技藝之皮脂粒治療方法之臨床實驗結果報導於下 列第1表。在第1表中之習知技藝活性物質皆在實驗期間 每天施用二次。 治療方法1. 1 Retin Α (商檫)是以在簡單乳霜基礎 灌度0.5%施用。 治療方法1.2之按摩是用手進行*而機械方式是用橄 欖油作爲按摩油。 治療方法1.3之咖啡因及茶葉鹼在簡單的膠中的濃度 分別爲2 %及0.2%。 使用熱及黃瞟昤之治療方法1.4使用來自La Prairie 之具有商品名“Cellular Body Contouring Gel”之產品 ,其能經由化學反應而增加皮虜表面的溫度。 治療方法1.5之脫皮是Μ懸浮於卡波坡膠的5%聚乙 烯珠每日二次強力地施用及沖洗掉之機械性脫皮。 治療方法1.6之血管活性藥用植物是來自Orlane商品 名爲 wRhyt+hne Du Co.rps” 之.商品。 (請先閱讀背面之注意事項再續寫本頁) 訂 本紙張尺度適用中國國家標準{ CNS ) A4規格(2丨OX297公釐) 46 45 0 9 Α? Β7 五、發明説明() 經濟部中央標準局員工消費合作社印製 第1表 傳統的皮脂粒治療方法之評估 治療方法 血流 TEWL 結實度 大腿 皮虜厚度 皮脂粒 過敏 g/m2/hr 直徑 等级 等级 1.1) RETIN A" 0.5S 底線 1 2.17 X X X 4 1 8週 X X X X X 4 0 t-k 12週 1.27 2.37 32¾ SX 4%(ns) 3 2.5 1.2)按摩 底線 1 2.41 X X X 4 1 8週 X X X X X 4 1 12週 0.97 1.97 61 -21 ns(ns) 4 1.25 1.3)咖啡因/茶窠鹼 底線 1 2.33 X X X 4 1 8週 X X X X X 4 1 12週 1.08 2.47 -3% -3¾ 2¾(ns) 3.75 1.25 1.4)熱/黃瞟昤 底線 1 2.61 X X X 4.25 1 8週 X X X X X 4.25 1.25 12週 1.03 2.23 4% -57, ns(-2X) 4 2 1.5)脫皮作用 底線 1 2.41 X X X 4.25 1 8週 X X X X X 4 1.5 12週 1.07 2.17 m -3% ns (-3¾ 4 2.25 1.6)血管活性之藥用植物 底線 1 2.23 X X X 4.25 1 8週 X X X X X 3.75 1.25 12週 1.01 2.41 η U ns(-3%) 3.75 1.5 * Johnson & Johnson公司視黃酸之商棲 ns=不明顯 (請先閲讀背面之注意事項再頊寫本頁) 訂 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 19 經濟部中央樣車局員工消費合作社印製 4 6 4 5 0 9 Α7 Β7 五、發明説明() 結果的前五欄作統計顯箸性分析,而只有治療方法1.1 之12週的血潢,結實度及大腿直徑的結果是顯箸的。(第 6及第7欄的皮脂粒駸重性及過敏之臨床分鈒是主觀性的 ,而不進行統計分析。) 關於該數據,只有治療方法1.1之視黃酸在基礎血滾 方面顯示明顯的改善,而治療方法1.3之咖_因及治療方 法1.5之脫皮作用只顯示在血流方面軽微但不明顯的增加 〇 有關第1表的TEWL及比較在丨2週之程度和底線的程度 *可見即使在12遇時,習知技藝之皮脂粒治療方法亦很少 逹到顯箸之增加。使用視黃酸的治療方法1.1顯示最佳的 增加但僅有10%。而本發明之治療方法能達到超過40%之 血流增加。 治療方法1.5之脫皮作用僅稍撤改善大腿結實度及直 徑,而治療方法1.1之視黃酸有較明顯之改善。而本發明 能逹到實質上更明顯之改善。 第1表中習知技S的皮脂粒治療方法僅顯示在皮虜厚 度上僅輕度,或不明顯的改善。 如第1表最後二攞所報導,治療方法1.1之提黃酸顯 示皮腊粒駸重性,如臨床之分级*之一般性降低,但其過 敏反應卻顯箸增加。 這些數據顯示己知的皮脂粒治療方法僅提供軽撤的功 效,而最好的結果是視黃酸,而次好的是脫皮作用。 在基礎血流,結資度,大腿直徑及皮賄粒一般狀況上 本紙張尺度適用中國國家揉準(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) i-Ltd.'s industry standard method for comparative colorimetric determination of skin color. In addition, record other subjective feelings such as irritation, burning and skin redness after application (please read the precautions on the back before filling out this page) Order ^ Standards in the Ministry of Economics. Μ} Μ X Consumer Cooperative Seal 464509 A7 B7 Ministry of Economic Affairs Printed by the Consumer Standards Cooperative of the Central Bureau of Standards 5. Description of Invention (), and this information is included in the Clinical Allergy Index, which has a scale of 0 to 5, 0 means no identifiable or reported allergy, and 5 means severe allergy. The clinical results of the conventional methods for the treatment of sebum granules are reported in Table 1 below. The conventional art active substances in Table 1 were applied twice daily during the experiment. Treatment method 1.1 Retin Α (商 檫) was applied at a simple cream base of 0.5%. The massage method of treatment 1.2 is performed by hand * and the mechanical method is to use olive oil as a massage oil. The concentration of caffeine and theophylline in simple gum in Treatment 1.3 was 2% and 0.2%, respectively. Therapeutic method using heat and scutellaria baicalensis 1.4 uses a product from La Prairie with the trade name "Cellular Body Contouring Gel", which can increase the temperature of the skin surface through chemical reactions. The peeling method of treatment method 1.5 is a mechanical peeling of 5% polyethylene beads suspended in carbopol gel and applied and washed off twice a day. The vascular active medicinal plant of treatment method 1.6 is a product from Orlande under the trade name wRhyt + hne Du Co.rps. (Please read the precautions on the back before continuing on this page) The paper size of this paper applies Chinese national standards { CNS) A4 specification (2 丨 OX297 mm) 46 45 0 9 Α? Β7 V. Description of the invention () Printed in Table 1 by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs, the evaluation of the traditional sebum granule treatment method. Blood flow TEWL Strong thigh skin thickness thickness sebum allergy g / m2 / hr diameter grade grade 1.1) RETIN A " 0.5S bottom line 1 2.17 XXX 4 1 8 weeks XXXXX 4 0 tk 12 weeks 1.27 2.37 32¾ SX 4% (ns) 3 2.5 1.2 ) Massage bottom line 1 2.41 XXX 4 1 8 weeks XXXXX 4 1 12 weeks 0.97 1.97 61 -21 ns (ns) 4 1.25 1.3) Caffeine / Theophylline bottom line 1 2.33 XXX 4 1 8 weeks XXXXX 4 1 12 weeks 1.08 2.47- 3% -3¾ 2¾ (ns) 3.75 1.25 1.4) Hot / yellow line 1 2.61 XXX 4.25 1 8 weeks XXXXX 4.25 1.25 12 weeks 1.03 2.23 4% -57, ns (-2X) 4 2 1.5) Peeling effect line 1 2.41 XXX 4.25 1 8 weeks XXXXX 4 1.5 12 weeks 1.07 2.17 m -3% ns (-3¾ 4 2.25 1.6) vascular active medicinal plant bottom line 1 2.23 XXX 4.25 1 8 weeks XXXXX 3.75 1.25 12 weeks 1.01 2.41 η U ns (-3% ) 3.75 1.5 * Johnson & Johnson's retinoic acid commercial habitat ns = not obvious (please read the precautions on the back before writing this page) The size of the paper is applicable to China National Standard (CNS) A4 (210 X 297) (Mm) 19 Printed by the Consumer Cooperative of the Central Sample Vehicle Bureau of the Ministry of Economic Affairs 4 6 4 5 0 9 Α7 Β7 V. Description of the invention () The first five columns of the results are used for statistical significance analysis, and only the treatment methods 1.1 to 12 weeks The results of blood donation, firmness and thigh diameter are remarkable. (The clinical analysis of sebaceous granules in severe and allergic columns in columns 6 and 7 is subjective and not statistically analyzed.) Regarding this data, only retinoic acid of the treatment method 1.1 showed significant basal blood roll. The improvement of the treatment method 1.3 and the peeling effect of the treatment method 1.5 and the treatment method 1.5 show only a small but insignificant increase in blood flow. TEWL on Table 1 and the degree of comparison and the degree of the bottom line in 2 weeks * It can be seen that even at 12 encounters, the sebum granule treatment method of the known technique rarely increases significantly. Treatment with retinoic acid 1.1 showed the best increase but only 10%. The treatment method of the present invention can achieve an increase in blood flow of more than 40%. The peeling effect of treatment method 1.5 only slightly improved thigh firmness and diameter, while treatment method 1.1 significantly improved retinoic acid. The present invention can achieve substantially more significant improvements. The sebum granule treatment method of the conventional technique S shown in Table 1 shows only a slight or insignificant improvement in the thickness of the skin. As reported in the last two paragraphs of Table 1, the flavulinic acid of treatment method 1.1 shows the severity of fur wax granules, such as the general reduction of clinical grade *, but its allergic response has increased significantly. These data show that known sebum granule treatment methods provide only withdrawal effects, with the best result being retinoic acid and the second best being peeling. In the general conditions of basic blood flow, funding, thigh diameter, and skin size, this paper size applies to China National Standard (CNS) A4 (210X297 mm) (Please read the precautions on the back before filling out this page) i -

•IT -20 - 464509 經濟部中央標準局員工消費合作社印裝 A7 B7 i、發明説明() 可達成改善*但卻造成顯著的過敏。習知技藉的治療方法 都未逹到TEWL明顯的增加或皮虜厚度之改善,其是皮霜健 康之基礎結構指標*這明顯地顯示習知技15的缺點。雖然 本發明不受限於待定的理論,似乎沒有一種習知技藝的治 療方法提供對皮慮的水障壁功能之顯著的持繪破壊以剌激 明顯的皮虜修復。 斩的皮脂粒沧痗方法 如上所述,本發明提供一種皮脂粒局部治療方法,其 降低皮虜的水障壁功能*較佳持鏞及長期增加TEWL 200至 300%或更多,至少8週的期間及較佳超過26週或直到達 到皮脂粒狀況令人滿意的改善,例如10至20週。 有利的TEWL之增加可藉由Μ合適的化學組成物或機械 破壊或溶劑萃取之持繙的治療而逹成,只要該治療方法能 足夠急遽地破#瞒_水障壁。本發明重要部分是在增加 TEWL之同時,也維持低的,可容忍的過敏反應,因用來破 壊障礙的腐蝕性化學藥品,用於萃取脂質之溶劑,及表面 活性劑都可爲非常具剌撖性的。 在本發明之特佳實施例中,發現相當高濃度未緩衝的 乳醴*是ex -羥酸之一倒,租雜他命Α椋概酸鹽或幕之組 合,能加成地增加TEWL。cr_羥酸破壊皮虜的水障壁及作 用爲TEWL增加劑。維他命A棕櫊酸鹽,一種視黃質,似乎 能抑制障壁功能之回復及延遲受ct -羥基治療增加之了EWL 之回愎正常。這些TEWL刺激特性可歸因於視黃質對皮*細 胞分化之影窖。維他命A棕櫊酸鹽和乳酸間的交互作用是 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) I---I---^--^-- (請先閱讀背面之注意事項再續寫本頁)• IT -20-464509 Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs A7 B7 i. Invention description () can achieve improvement * but cause significant allergies. None of the treatment methods used in the conventional techniques has shown a significant increase in TEWL or an improvement in the thickness of the skin, which is an indicator of the basic structure of the skin cream. This clearly shows the shortcomings of the conventional technique 15. Although the present invention is not limited to the theory to be determined, there does not appear to be a conventional treatment method that provides a significant breakthrough in the function of the skin barrier of the skin barrier to stimulate apparent skin repair. Method for chopping sebum granules As described above, the present invention provides a local treatment method for sebum granules, which reduces the function of the water barrier of the skin grafts. * It is better to hold and increase TEWL 200 to 300% or more for a long period of at least 8 weeks. During and preferably over 26 weeks or until a satisfactory improvement in sebum status is achieved, such as 10 to 20 weeks. The beneficial increase in TEWL can be achieved by the treatment of appropriate chemical composition or mechanical rupture or solvent extraction, as long as the treatment can be broken quickly enough. The important part of the present invention is that while increasing TEWL, it also maintains a low, tolerable allergic reaction. Corrosive chemicals used to break barriers, solvents used to extract lipids, and surfactants can be very specific. By nature. In a particularly preferred embodiment of the present invention, it has been found that a relatively high concentration of unbuffered lactam * is one of ex-hydroxy acids, and a combination of thiamine or sodium salt can increase TEWL additively. cr_hydroxy acid breaks the water barrier of the skin and acts as a TEWL increasing agent. Vitamin A palmitate, a retinoid, appears to be able to inhibit the recovery of the barrier function and delay the recovery of EWL which is increased by ct-hydroxy treatment. These TEWL-stimulating properties can be attributed to the crypts of retinin-derived * cell differentiation. The interaction between vitamin A palmitate and lactic acid is that this paper size applies the Chinese National Standard (CNS) A4 specification (210 × 297 mm) I --- I --- ^-^-(Please read the back (Notes continued on this page)

,1T 21 經濟部中央標準局員工消費合作社印製 46 45 0 9 A7 B7 五、發明説明() 相當未預期到的。 本發明的較佳實施例當局部施用在皮慮時,據信可Μ 長期及嚴重地剝落皮虜而造皮廉細胞之鼹重損失,及更重 要地破壞正常的障壁功能而使TEWL增加至較佳高達200至 300%。雖然物理方法可用來逹成這些效果,本發明發現 介於5-10%未緩衝的乳酸及0. 1%-3.05¾維他命Α棕櫊酸 邇可逹成該結果而僅造成中度過敏。發現6 %乳酸及0.5 %雒他命A棕櫊酸翮之組合是特別有效。長期的高TEWL程 度被認為會引發關鍵性的皮膚生長因子,如細胞間質素及 轉換生長因子,之釋出,而迮成剌激真皮-表皮生長及血 管生成效應。這類的治療方法可能太轂苛而不能用於除部 皮ft,但在易受皮脂粒影饗的大腿,手臂及胸部區域之皮 虜是較具有抗性的。以上述紐合物之治療增厚及改善含喊 皮脂粒的真皮及表皮,而血管生成效果改善長程的血流狀 況。 爲了逹成TEWL更進一步及更持纗的增加,發現添加特 定的腦甙,第I或第E型,能和上述組成物加成地發揮功 效。I及E可了解是藉由指對應的腦酿胺而意謂特定的分 子结構,見例如Rieger,第2表,第88頁。在皮虜的新陳 代謝中,腦酿胺是由神經鞘氨醇的酿化作用而製成的,而 腦甙是腦醯胺的糖化作用產物。腦酿胺和腦甙只佔皮*脂 質很小的百分比,及是存在於皮#外層,而神經鞘氨醇, 其先質*主要是發現於皮膚基層。神經鞘氨醇亦以顯箸的 量存於剝離的角質層細胞中,因腦醢胺在脫皮過程中被酵 本紙張尺度適用中國國家標準(CNS ) Ad规格(210Χ297公釐) (請先閲讀背面之注意事項再禎寫本頁) ,ιτ 22 464509 A71T 21 Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs 46 45 0 9 A7 B7 V. Description of the invention () Quite unexpected. The preferred embodiment of the present invention, when topically applied to dermatologically, is believed to cause long-term and severe peeling of the skin cells, resulting in heavy loss of dermal ligament cells, and more importantly disrupting normal barrier function and increasing TEWL to It is preferably up to 200 to 300%. Although physical methods can be used to achieve these effects, the present invention has found that between 5-10% unbuffered lactic acid and 0.1% -3.05¾ vitamin A palmitic acid can produce this result and cause only moderate allergies. It was found that a combination of 6% lactic acid and 0.5% betaine A palmitate was particularly effective. Long-term high TEWL levels are thought to trigger the release of key skin growth factors such as interstitial cells and transforming growth factors, which in turn stimulates dermal-epidermal growth and angiogenesis effects. This type of treatment may be too harsh to be used on the skin, but it is more resistant to the skin in the thighs, arms and chest areas that are susceptible to sebum. The treatment with the above-mentioned button compounds thickens and improves the dermis and epidermis containing shout sebum particles, and the angiogenesis effect improves long-term blood flow conditions. In order to achieve further and sustained increase in TEWL, it was found that the addition of a specific cerebroside, type I or type E, can exert an additive effect with the above composition. I and E can be understood to mean specific molecular structures by referring to the corresponding ceramide, see, eg, Rieger, Table 2, page 88. In the metabolism of Pirup, brain ceramide is made by sphingosine, and cerebroside is the glycation product of ceramide. Cerebral amines and cerebrosides account for only a small percentage of the lipids of the skin, and are present in the outer layer of the skin, while sphingosine, the precursors of which are mainly found in the base layer of the skin. Sphingosine is also stored in exfoliated stratum corneum cells in a significant amount. Because ceramide is fermented during the peeling process, the paper size applies the Chinese National Standard (CNS) Ad Specification (210 × 297 mm) (Please read first (Notes on the back are reproduced on this page), ιτ 22 464509 A7

經濟部中央標準局員工消費合作社印製 素分解。 本發明之破壊障壁的治療方法釋出訊息至皮虜的較底 層Μ增加如腦醯胺的脂質之合成及修復該壁障。本發明的 非限制性的假說是腦甙I或I的施用會干擾此合成作用, 而粗止障壁之自我修復。除了腦甙I或Π之外的脂質合成 之一般抑制劑*或皮虜脂質合成之其他終產物,也可爲上 述治療方法之有效的補充物Μ維持增加的TEWL及促進長時 期的皮*修復。 在Dr. Sergio Curri於1994年3月於西班牙巴塞隆納 Cosmetic &amp; Toiletry Convention發表的文章指出,蛋白 質激酶C的抑制,例如藉由神經鞘氨醇,可爲有用的皮脂 粒治療方法。該建議意謂著腦甙在治療皮脂粒上沒有幫助 。在未報導於此的試驗中發現就本發明的目的而言,磷脂 質,腦醯胺及神經鞘氨醇在作爲障壁修復抑制爾之功效很 小,進一步發現腦甙本身在控制TEWL或治療皮脂粒方面沒 有幫助。 皮脂粒治療方法的進一步有利及重要的功能是降低或 除去為皮脂粒之令人不悅的特激之皮下脂肪塊之蓄積。依 據本發明之目檷,藉由剌激脂質的新陳代謝*斜如*經由 增加皮*酵素ATPase及蛋白質激酶C,能逹成皮*之蓄積 脂肪之緩慢的自然分解。 意外地發現藉由將腦甙納入局部施用的化粧組成物中 ,可抑制脂質的新陳代謝。本發明並不受限於某一特定理 論,而只受限於後附的申請專利範圍,似乎腦甙在角質層 (請先閱讀背面之注意事項再填寫本頁) 、?τ 本紙張尺度適用中國國家標準(CNS ) A4规格(2丨0X297公釐) 6 4 45 0 9 A7 B7 五、發明説明( 經濟部中央標準局員工消費合作杜印裝 障壁的再生上扮演特定的角色。當該障壁被破壞時,特定 的訊號被釋出,而引發表皮及真皮新陳代謝作用之活化。 這些訊號中的一些活化了新的表皮脂質之合成作用以修復 該障壁及將TEWL回復正常。此修復作用會關閉貪責话化表 皮及真皮新陳代謝作用(及活化皮下合成新的血管)的訊 號。所邃擇的腦甙(但非腦醯胺或神經鞘氨醇)干擾障壁 的修復至表皮及真皮新陳代謝作用的活化可維持一段長時 間,而產生能改善皮脂粒狀況之改變。由所選擇的腦甙所 造成的障壁修復之干播並不會造成皮虜之負面效應。反而 ,似乎是干擾表皮脂質之生成,而其能栝化表皮及真皮新 陳代謝作用及能維持數遇及數月的期間。這些觀念都由報 告於下的臨床試驗結果所證實。 這些有關腦甙之障壁修復抑制劑的角色之結論及結果 是相雷意外的,因傳統的教導指出腦甙應修復受破壊的障 壁。 結論為腦甙的效應是非常待定及是在角質層上,但此 理論之提供僅是依所了解的本發明而說明本發明的機制。 進步的硏究也許會顯示其他的機制。腦甙亦可能透過蛋白 質擻酶C的作用而直接影罌皮下區域脂肪腊質的新棟代謝 作用。 當纳入所述的局部治療方法時,腦甙組成成分具有長 程,例如超過10至20遇,的功效而改善皮慮品質及皮脂粒 狀況。 如下列所述的實驗顯示,TEWL增加劑,特別是乳酸, --------:--V-- (請先聞讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國國家榇準(CNS ) A4規格(2IOX297公釐) 24 46 45 0 9 Α7 Β7 經濟部中央標準局員工消費合作社印製 五、發明説明() 和視黃質,特別是維他命A棕撋酸鹽及皮#障壁修復之抑 制劑*特別是腦甙,較佳是第I型或第I型腦甙,之組合 能產生TEWL持續及長期的增加及障壁功能之破壞,而導致 上述有利的皮*修復及皮脂粒改善的效果。 TRtf丨.埔加_ :卸某镑酸 較佳地,TEWL增加劑可溶於水或有些極性的氫化醇以 提供納入化粧品基礎的栝性組成成分之有效溶液。除了乳 酸外,可使用其他許多α-羥酸。在本發明中,乳酸是特 佳的TEWL增加劑,其具有良好的功效及為天然存在於皮暾 ,細胞間液及血液中的物質。除了乳酸外,其他較佳者為 乙醇酸,水楊酸及這些酸之混合物。 爲了具有所要的降低pH值及增加TEWL之性質,以及化 粧品之可相容性及中度的水或氫化醇之可溶性,較佳的羥 苯酸具有低於約250,及較佳低於約175 *的分子量。 許多可用的羥基羧酸描述於國際專利申請W0/94/O6640 。一些其他的ex -羥基羧酸敘述於Yu及Van Scott之美國專 利第4,363,815號及第5,091, 171號。逑於這些文獻的酸及 酸當量,及其公布部分僅納於此供參考*及當符合上述條 件時可用於本發明。較佳地1用於發明組成物之羥基 酸較佳是直鍵或支鏈的腊肪族酸,且脂肪族骨架不含超過 3傾的取代基,該取代基是非鹼性的及選自羥基,醛,酮 ,羧基,氯及硝基。 雖然酸性及水或氫化醇可溶性是本發明的α-羥基酸 之所要的特性*但任何造些性質之極端,如無機酸所顯示 I---------V-- (請先閲讀背面之注意事項再填寫本頁) 、1Τ 本紙張尺度適用中國國家標準(CNS &gt; Α4规格(210X 297公釐) 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明() 的,是不利的因不僅會引起過敏亦會造成如灼傷,損傷及 皮下穿透等鹾重的臨床上之狀況。低分子量物質有時亦顯 示這些不利的性質,其可能顯示不尋長及不可預測,及通 常有害的特殊行爲。 其他可用於本發明之這類羥基腊肪族酸較佳為單羧酸 ,其選自2-羥基-η-丁酸,2-羥基-異丁酸,2-羥基-η-戊 酸,2_羥基-異戊酸* 2-羥基-η-己酸,2-羥基-異己酸。 其雙-或多氫類似物亦可使用,例如,其2,Χ-二羥基類似 物,其中X是3至6的整數,視適合各單羥基酸而定,顯示 在一磺原子之第二羥基取代基之磷原子位置而非該一或二 碳原子。較佳地,這類二羥基酸平衡了因如上述該第二羥 基之更疏水性部分造成的附加電負性。合適的二羥基酸包 括 aaleic酸,((:}1.(:0〇[1)8及壬二酸,HOOC.iClUh.COOH。 睦壁功能冏復柚制剷 依據本發明,較佳的障壁功能回復之抑制劑是視黃質 ,例如tretinoin,或視黃酸。然而,許多視黃質或視黃 酸是不穩定的及不適合行銷於化粧品之局部治療組成物中 。雒他命A棕櫊酸鹽是特別穩定的視黃質,因此較佳用於 本發明。其他適甩於如本發明組成物之配方的穩定的視黃 質包括視黃基乙酸鹽及視黃醇。 其他具有連結至脂肪酸鏈的穩定的視黃基而提供油穩 定性及在描述於此的局部施用載體之良好可溶性的視黃質 ,也可用於本發明組成物中。在本發明方法中,貨架壽命 期也許不是重要的。因此,若局部施用配方是需要時才製 本紙張尺度適用中國國家樣準(CNS ) Α4規格(2丨ΟΧ297公嫠) 26 --------.I— V —— 〈請先聞讀背面之注意事項再填寫本頁)Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs. The treatment method for breaking the barrier of the present invention releases a message to the lower layer M of the skin corpuscle that increases the synthesis of lipids such as ceretonamine and repairs the barrier. The non-limiting hypothesis of the present invention is that the administration of cerebroside I or I would interfere with this synthesis and crudely stop the self-repair of the barrier. General inhibitors of lipid synthesis other than cerebroside I or Π * or other end products of dermal lipid synthesis, can also be an effective supplement for the above-mentioned treatment methods to maintain increased TEWL and promote long-term skin * repair . An article published by Dr. Sergio Curri at the Cosmetic &amp; Toiletry Convention in Barcelona, Spain, in March 1994 states that inhibition of protein kinase C, such as sphingosine, can be a useful treatment for sebum particles. The suggestion means that cerebroside is not helpful in treating sebum particles. In experiments not reported here, it has been found that for the purposes of the present invention, phospholipids, ceramides, and sphingosine have little effect as barrier repair inhibitors, and further found that cerebroside itself is controlling TEWL or treating sebum Grain doesn't help. A further advantageous and important function of the sebum granule treatment method is to reduce or eliminate the accumulation of the unpleasantly stimulating subcutaneous fat mass which is a sebum granule. According to the purpose of the present invention, by stimulating the metabolism of lipids * slopingly * by increasing the skin * enzyme ATPase and protein kinase C, the skin * 's accumulated fat can be slowly and naturally broken down. It was unexpectedly found that by incorporating cerebroside into a topically applied cosmetic composition, the metabolism of lipids can be suppressed. The present invention is not limited to a specific theory, but is limited only by the scope of the attached patent application. It seems that cerebroside is in the stratum corneum (please read the precautions on the back before filling this page),? Τ This paper size applies China National Standard (CNS) A4 specification (2 丨 0X297 mm) 6 4 45 0 9 A7 B7 V. Description of the invention (Employees of the Central Bureau of Standards, Ministry of Economic Affairs, Consumer Consumption Cooperation, Du Printing Barrier Regeneration plays a specific role. When the Barrier When destroyed, specific signals are released, triggering the activation of the epidermal and dermal metabolism. Some of these signals activate the synthesis of new epidermal lipids to repair the barrier and restore TEWL to normal. This repair effect will be turned off Corruption signals signals to the epidermal and dermal metabolism (and activates the synthesis of new blood vessels under the skin). The selected cerebroside (but not ceramide or sphingosine) interferes with the repair of the barrier to the epidermal and dermal metabolism. Activation can be maintained for a long period of time, resulting in changes that can improve the condition of sebum granules. Dry sowing of the barrier repair caused by the selected cerebroside does not cause skin captives The negative effect. Instead, it seems to be interfering with the production of epidermal lipids, which can metabolize the epidermal and dermal metabolism and can sustain periods of time and months. These concepts are confirmed by the results of clinical trials reported below. These The conclusions and results about the role of cerebroside's barrier repair inhibitors are unexpected, because traditional teachings point out that cerebroside should repair the cleft dysfunction. It is concluded that the effect of cerebroside is very uncertain and is in the stratum corneum, However, this theory is only provided to explain the mechanism of the present invention according to the understanding of the present invention. Progressive research may show other mechanisms. Cerebroside may also directly affect fatty wax in the subcutaneous region through the action of protein 擞 enzyme C. When the topical treatment method is incorporated, the cerebroside composition has a long-term effect, such as more than 10 to 20 encounters, and improves the quality of skin concerns and the condition of sebum granules. The experiments described below show that , TEWL increasing agent, especially lactic acid, --------:-V-- (please read the precautions on the back before filling this page) Furniture Standard (CNS) A4 (2IOX297 mm) 24 46 45 0 9 Α7 Β7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention () and retinoids, especially vitamin A palmitate and The inhibitor of skin #repair wall repair * especially cerebroside, preferably type I or type I cerebroside, the combination can produce continuous and long-term increase of TEWL and the destruction of the barrier function, leading to the above-mentioned favorable skin repair And the effect of improving sebum granules. TRtf 丨. Pujia_: Unloading a certain pound of acid. Preferably, TEWL increasing agent is soluble in water or some polar hydrogenated alcohols to provide an effective solution that incorporates the basic ingredients of cosmetics. In addition to In addition to lactic acid, many other α-hydroxy acids can be used. In the present invention, lactic acid is a particularly good TEWL increasing agent, which has good efficacy and is a substance naturally present in the skin, intercellular fluid, and blood. In addition to lactic acid, glycolic acid, salicylic acid and mixtures of these acids are preferred. In order to have the desired properties of lowering the pH and increasing TEWL, as well as the compatibility of cosmetics and the solubility of moderate water or hydrogenated alcohols, the preferred hydroxybenzoic acid has less than about 250, and preferably less than about 175 * Molecular weight. Many useful hydroxycarboxylic acids are described in International Patent Application WO / 94 / O6640. Some other ex-hydroxycarboxylic acids are described in U.S. Patent Nos. 4,363,815 and 5,091,171 to Yu and Van Scott. The acids and acid equivalents in these documents, and their published parts, are incorporated herein by reference only * and can be used in the present invention when the above conditions are met. Preferred 1 The hydroxy acid used in the composition of the invention is preferably a linear or branched aliphatic acid, and the aliphatic skeleton does not contain more than 3 dip substituents, which are non-basic and are selected from hydroxy , Aldehyde, ketone, carboxyl, chlorine and nitro. Although the acidity and the solubility of water or hydrogenated alcohol are the desired characteristics of the α-hydroxy acid of the present invention *, any extreme of these properties, as shown by the inorganic acid I --------- V-- (please first Read the notes on the back and fill in this page), 1T This paper size applies the Chinese national standard (CNS &gt; A4 size (210X 297 mm)) Printed by A7 B7 of the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs It is unfavorable because it will not only cause allergies, but also cause serious clinical conditions such as burns, injuries, and subcutaneous penetration. Low molecular weight substances sometimes also show these unfavorable properties, which may show no longevity and unpredictability. , And special behaviors that are generally harmful. Other such hydroxy wax fatty acids useful in the present invention are preferably monocarboxylic acids selected from 2-hydroxy-η-butyric acid, 2-hydroxy-isobutyric acid, 2- Hydroxy-η-valeric acid, 2-hydroxy-isovaleric acid * 2-hydroxy-η-hexanoic acid, 2-hydroxy-isohexanoic acid. Its bis- or polyhydrogen analogs can also be used, for example, its 2, ×- Dihydroxy analogs, where X is an integer from 3 to 6, depending on which monohydroxy acid is suitable The position of the phosphorus atom of the second hydroxy substituent of the atom is not the one or two carbon atoms. Preferably, this type of dihydroxy acid balances the additional electronegativity caused by the more hydrophobic portion of the second hydroxy group as described above. Suitable dihydroxy acids include aaleic acid, ((:} 1. (: 0〇 [1) 8 and azelaic acid, HOOC.iClUh.COOH. Mubi function 冏 multiple grapefruit shovel according to the present invention, a preferred barrier Functional inhibitors are retinoids, such as tretinoin, or retinoic acid. However, many retinoids or retinoic acid are unstable and unsuitable for sale in topical therapeutic compositions for cosmetics. Vitamin A Brown 櫊Acid salts are particularly stable retinoids and are therefore preferred for use in the present invention. Other stable retinoids suitable for formulations such as the compositions of the present invention include retinyl acetate and retinol. Others have a link to Stable retinyl fatty acid chains that provide oil stability and good solubility in the topically applied carriers described herein may also be used in the composition of the present invention. In the method of the present invention, the shelf life may not be Important. Therefore, if applied topically The formula is made only when needed. The paper size is applicable to China National Standard (CNS) Α4 specification (2 丨 〇 × 297 公 嫠) 26 --------. I— V —— <Please read the precautions on the back before reading (Fill in this page)

、1T 6 4 45 0 9 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明( 造及不會貯存很長一段時間的話,所選的視黃質的穩定性 就會較不顯箸,而可使用較不安定的視黃質。 許多活性視黃質可用於本發明,如列於Π i gman美國 專利第5,051,499號,其公開在此納入供參考。其他這類 的視黃質包括維他命A醛,維他命A酸,維他命A酯,視 黃酸,乙視黃酸酯(etretinate),酸視黃素(acitretin) 視黃質酯,13-順及13-反視黃酸之酯類及瞌胺類·及視黃 基武。 曈壁修復夕抑制割 如上所逑,發現腦甙於本發明具有作為障壁修復的抑 制劑之有利功能,該功能被認爲是經由抑制納入於角質層 及因而提供正常水障壁功能之脂質合成而逹成的。在符合 此觀念下,其他物質亦被認為具有所要的抑制障壁修復的 角色。 用於本發明的腦甙可以數棰商品形式取得。有時是以 配糖神經鞘脂質(GSL)供應,該詞是指任何具有神經鞘 基的脂質和糖連接。如所供應的,腦甙是GSL之主要成 分*其有時是自植物或動物的粗生物分離物。第I型及第 I型牛腦腦甙之較純〉的混合物可自Sigiw Chemical Co.取得,型錄號C 4905。 組成成分之相對比例 本發明的皮脂粒治療組成物之強度的限制是其引發過 敏的程度。受皮脂粒影缕區域的皮虜一般是比臉部皮#較 不敏感,在其上曾Μ如能促進皮虜再生“防皺乳箱”或“ 本紙張尺度適用中國國家標準(CNS ) Α4规格(210Χ297公釐} (請先閱讀背面之注意事項再填寫本頁) ,1Τ 27 經濟部中央標準局員工消費合作社印製 45 Ο 9 A7 ---------- 五、發明説明() 防老化乳霜”的配方測試本發明組成物中的一些可能的組 成成分。因此,因爲受皮脂粒影镨的區域之較低的組織敏 感度,新的皮腊粒治療組成物的較佳配方可採用較高比例 ,或容許比用於臉部皮慮的乳霜之較高範圍的活性組成成 分比例。 依其強度及剌撖性而定,TEWL增加劑,較佳是α -羥 基羧酸,用於局部治療組成物之有用的比例是該組成物之 自1至15重量%,及較佳的中程比例自5至10%,特別是 乳酸或乙醇酸。 當視黃質用作細胞更新剌撖劑時,有用的比例是自約 0.005至約6.0重量% *較佳是1.0至4.0重量% ,雖然自0.1 至1. 0範圍的比例都被認為具活性,但較不具功效。 當腦甙或腦甙用作本發明的障壁修復之抑制劑時,障 壁修復之抑制劑的有用範圍是自約0.01至約5%,較佳的 範圍是自約0.05至約1 %,特佳是自約0. 1至約0.5%。 除非另外說明,或自內容中明顯可見,用於此的比例 是基於組成物總重的重量比例,及是指活性組成成分或對 等者之比例。 治痔鉬成物夕nii值 依TEWL增加劑的酸性而定,較佳的ΡΗ值是有些酸性的 ,且實際上中度但可承受的酸性被認為能促進障壁之破壊 。因此,較佳的PH值是介於約3. 0至6. 2,而Μ 4. 5至5.0較 佳。 蓰摆袢之沛成成分 本紙張尺度適用中國國家標準(CNS ) Α4規格(2ΙΟΧ297公釐) (請先聞讀背面之注意事項再填寫本頁) 、1Τ 28 五、發明説明() A7 B7 經濟部中央標準局員工消費合作社印¾ 本發明之非必需,但重要的選擇性恃性是包含能立卽 改善皮脂粒外觀之一種組成成分。這可經由立即增加血流 及除去過多的液體而達成。已知的利尿物質 &gt; 如咖琲因, 茶葉齡,水楊酸甲基酯及其他類似物質都很有效。較佳的 物質是 PRONALEN C (商檫,Centerchem, Inc.),能增進 該產品最初接受性的一種天然生物抽出物。 一般而言,纳入於依據本發明的皮脂粒治療組成物的 有用的選擇性之附加組成成分,可單獨或一起納入,為利 尿劑,抗過敏劑及抗氧化劑,較佳是K已知在局部施用的 化粧品中有效的濃度,例如掴別自約0.5至7.0%,及更佳 約1至3 %。 利尿劑促進淋巴排除及脂質新陳代謝,及造成對消費 者而言明顯的皮脂粒狀況之立即的短程改善。合適的利尿 劑為血管舒張劑,如咖啡因,黃晡呤等。 抗過敏劑及抗氧化劑可用來增加對持續之增加的TEWL 之忍受程度。合適的抗過敏劑爲可樂木油出物,綠茶,蘆 备等*而合適的抗氧化劑爲BHT,NDGA,維生素E及C, 及掊酸丙酯。 合適的選擇性組成成分之納入提供一種完整及平衡的 皮脂粒治療方法,其產生該情況快速及立卽明顯的改善及 長程的結構性改進,而同時也控制了過敏反應。 旆用麵酱及捃蜜 述於此的發明之皮脂粒治療組成物之施用率一般介於 每平方公分皮虜約0,01至0.5 mg活性酸組成成分之間,而 (請先閲讀背面之注意事項再填寫本頁) 訂 本紙張尺度逋用中國圉家揉準(CNS &gt; A4規格(210X297公釐) 29 A 7 B7 經濟部中央標準局員工消費合作杜印製 五、發明説明() 該酸爲低分子量親水性酸,如C(-羥基羧醴,以自0.05至 0·2 mg/cm2之範圍較佳。化粧乳霜一般以約2-3 mg/cm2 施用。Μ活性組成成分比例為約0. 15至约30重量%,這给 予话性組成成分的可能施用率自約0.003 mg/cma至0.9 mg/cma。較佳的範圍是自約0.01至0.5 ffig/cms,而Μ每 單位皮虜自0.05至0.2 ng/craa之範圍更佳。使用總共約 7%活性組成成分之較佳比例,能给予約0.15至0.2 mg/ cm8的較佳施用率。 此劑量較佳每天2次施用至需要治療的皮盧區域。每 天三或四次之更常的施用只會浪費產品而不提供更好的功 效,而每天一次之較少的施用會造成功效之降低。在清洗 ,洗澡及游泳後偁爾可增加施用,至多約每天六次。 另外的曈壁破鹿方法 除了 Kcc-羥基酸及視黃質的組合破壞水障壁之外, TEWL亦可經由角質層剝落,溶劑萃取等而增加。 丙酮 亦發現當持鏞一段長時間,例如二β月*每天或 每隔一天Μ丙酮漂洗可破壊皮虜的水障壁。生物物理測量 指出丙嗣漂洗方法應該達成上述長程皮霜修復的效果。丙 酮可在脂質形成特將其除去及干換障璧之修復。然而,丙 _是非常剌檄性的,可燃的,及有毐的,及不建議使用。 如第2表的數據證實本發明觀念之廣泛範圍並不限於 施用化粧組成物Μ破壊皮慮水障壁及增加TEWL,亦可擴及 其他物理及生理-化學治療方法。 嘐帶黏剝 以黏膠塗覆的賽路分膠帶黏剝皮_ 5至10次 (請先閲讀背面之注意事項再填寫本頁)1T 6 4 45 0 9 A7 B7 Printed by the Consumers' Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the invention (If it is manufactured and will not be stored for a long time, the stability of the selected retinoid will be less significant 箸Instead, less stable retinoids can be used. Many active retinoids can be used in the present invention, as listed in US Patent No. 5,051,499, which is incorporated herein by reference. Other such retinoids include Vitamin A aldehyde, Vitamin A acid, Vitamin A ester, Retinic acid, etretinate, acid retinin, 13-cis and 13-trans-retinoic acid esters And retinoids and retinoids. Inhibition of wall repair and inhibition as described above, it was found that cerebroside has an advantageous function as an inhibitor of barrier repair in the present invention. This function is considered to be incorporated into the stratum corneum through inhibition and thus It is formed by the synthesis of lipids that provide normal water barrier function. In accordance with this concept, other substances are also considered to have the desired role in inhibiting the repair of the barrier wall. The cerebral glycosides used in the present invention can be obtained in the form of a number of commercial products. Sometimes they are With sugar Supply via transsphingomyelin (GSL), the term refers to any lipid and sugar linkage with a sphingomyelin. As supplied, cerebroside is the main component of GSL * which is sometimes a crude biological isolate from a plant or animal. A relatively pure mixture of Type I and Type I bovine brain cerebroside can be obtained from Sigiw Chemical Co., Catalog No. C 4905. Relative Ratio of Compositions The limitation of the strength of the sebum granule therapeutic composition of the present invention is its The degree of allergies. The skin captives in the areas affected by sebum are generally less sensitive than the facial skin #, on which there have been "wrinkle-resistant milk boxes" or "this paper standard applies to China Standard (CNS) Α4 specification (210 × 297 mm) (Please read the precautions on the back before filling out this page), 1T 27 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 45 Ο 9 A7 --------- -V. Description of the invention ("Anti-aging cream" formula tests some possible constituents in the composition of the present invention. Therefore, because of the lower tissue sensitivity of the areas affected by sebum grains, new skin waxes The preferred formulation of the therapeutic composition may be Ratio, or allowable range of active ingredient ratios higher than those of creams for facial dermatology. Depending on its strength and nature, TEWL increasing agents, preferably alpha-hydroxycarboxylic acids, are used topically A useful proportion of the therapeutic composition is from 1 to 15% by weight of the composition, and a preferred intermediate range is from 5 to 10%, especially lactic acid or glycolic acid. When retinol is used as a cell regeneration tincture A useful ratio is from about 0.005 to about 6.0% by weight * preferably 1.0 to 4.0% by weight. Although ratios ranging from 0.1 to 1.0 are considered to be active, they are less effective. When cerebroside or brain When used as an inhibitor of the barrier repair of the present invention, a useful range of the inhibitor of the barrier repair is from about 0.01 to about 5%, preferably from about 0.05 to about 1%, particularly preferably from about 0. 1 to about 0.5%. Unless otherwise stated, or apparent from the content, the proportions used herein are weight proportions based on the total weight of the composition and refer to the proportions of the active ingredients or their equivalents. The nii value of hemorrhoid molybdenum products depends on the acidity of the TEWL increasing agent. The preferred pH value is somewhat acidic, and in fact, moderate but tolerable acidity is considered to promote the breakage of the barrier. Therefore, the preferred pH value is between about 3.0 to 6.2, and M 4.5 to 5.0 is more preferred. The composition of this paper is based on the Chinese National Standard (CNS) A4 specification (2IO × 297 mm) (please read the precautions on the back before filling this page), 1T 28 V. Description of invention () A7 B7 Economy Printed by the Consumer Standards Cooperative of the Ministry of Standards of the People's Republic of China ¾ The non-essential but important selectivity of the present invention is to include a component that can improve the appearance of sebum granules. This can be achieved by immediately increasing blood flow and removing excess fluid. Known diuretics &gt; such as caffeine, tea age, methyl salicylate and other similar substances are effective. The preferred substance is PRONALEN C (commercial, Centerchem, Inc.), a natural biological extract that enhances the initial acceptance of the product. In general, useful and selective additional ingredients incorporated in the sebum granule therapeutic composition according to the present invention can be incorporated alone or together as diuretics, anti-allergic agents and antioxidants, preferably K is known locally Effective concentrations in the applied cosmetics are, for example, from about 0.5 to 7.0%, and more preferably from about 1 to 3%. Diuretics promote lymphatic rejection and lipid metabolism, and cause an immediate short-term improvement in sebaceous granule status that is apparent to consumers. Suitable diuretics are vasodilators such as caffeine, baicalin and the like. Anti-allergic and anti-oxidants can be used to increase tolerance to a continuously increasing TEWL. Suitable anti-allergic agents are cola wood oil extract, green tea, asparagus, etc. * and suitable antioxidants are BHT, NDGA, vitamin E and C, and propyl gallate. The inclusion of suitable optional ingredients provides a complete and balanced treatment of sebum granules that produces rapid and significant improvements in the condition and long-term structural improvements, while also controlling allergic reactions. The application rate of the sebum granule therapeutic composition of the invention described herein with noodle sauce and honey is generally between about 0.01 to 0.5 mg of active acid component per square centimeter of skin, and (Please read the Note: Please fill in this page again.) The size of the paper used for this edition is based on Chinese standards (CNS &gt; A4 size (210X297 mm) 29 A 7 B7 Printed by the staff of the Central Bureau of Standards of the Ministry of Economic Affairs. The acid is a low molecular weight hydrophilic acid, such as C (-hydroxycarboxamidine, preferably in the range from 0.05 to 0.2 mg / cm2. Cosmetic creams are generally applied at about 2-3 mg / cm2. Active ingredients The ratio is from about 0.15 to about 30% by weight, which gives a possible application rate of the sexual component from about 0.003 mg / cma to 0.9 mg / cma. The preferred range is from about 0.01 to 0.5 ffig / cms, and M The range from 0.05 to 0.2 ng / craa per unit of skin is better. Using a preferred ratio of a total of about 7% active ingredients can give a preferred application rate of about 0.15 to 0.2 mg / cm8. This dose is preferably 2 per day Application to the area of Pilou that requires treatment. Three or four more daily applications will only waste the product and Provides better efficacy, and less application once a day will cause a decrease in efficacy. After washing, bathing and swimming, you can increase the application, up to about six times a day. Another method of breaking the deer wall besides Kcc-hydroxyl In addition to the combination of acids and retinoids that damage the water barrier, TEWL can also be increased by exfoliation of the stratum corneum, solvent extraction, etc. Acetone has also been found to be held for a long time, such as two beta months * daily or every other day acetone rinse It can break the water barrier of the skin. Biophysical measurements indicate that the rinsing method should achieve the above-mentioned long-term skin cream repair effect. Acetone can remove it in the formation of lipids and dry the barrier to repair. However, __ Natural, flammable, and flammable, and not recommended for use. For example, the data in Table 2 confirms that the broad scope of the concept of the present invention is not limited to the application of the cosmetic composition M to break water barriers and increase TEWL. And other physical and physio-chemotherapy methods. 嘐 Adhesive peeling with adhesive-coated Sailu tape adhesive peeling _ 5 to 10 times (Please read the precautions on the back before filling this page)

、1T 本紙張尺度適用中國國家標率(CNS ) A4規格(2丨OX297公釐) A 7 B7 經濟部中夬標隼局員工消費合作杜印製 五、發明説明() 亦是另一種有效的破壞障壁方法,其增加TEWL 2至10倍 ,依個體的特定反應而定。在8週的期間此治療方法可造 成和有用的皮脂粒治療一致的正面的生物效應。此治療方 法之正面結果進一步證實了本發明廣泛的技術範畴。然而 ,作為商業化方法,膠帶黏剝有一些缺點,包括但不限於 膠帶黏剝的反應因痼體而差異很大,及必需用昂貴的實驗 室儀器來監測障壁的功能。 表面活性劑剝落 亦發現每天使用強的含水的表面活性 劑可長期破壞障壁。每天使用表面活性劑,如10%硫酸十 二烷基納二次是足夠的。當單獨使用時,使用超過8週時 SLS是過敏性的。添加0.1%的神經鞘氨醇可有效地控制 及減少長程過敏反應,使得該治療方法被認為溫柔至足Μ 用作本發明之實際實施例。當也可包括抗氧化劑及立即效 果之抗過敏劑,如可樂果抽出物*腦甙不能納入含有神經 鞘氨酸的組成物中。 若需要的話*住何這些在增加TEWL有效的方法或非乳 霜治療方法,都可和局部施用之含有視黃質及,可選擇地 ,腦甙之乳箱一起使用,Μ延長TEWL之增加及皮®修復過 程。 合滴:&gt; 載腾 任何習慣上使用來傳送剌激皮®再生的酸至皮*之化 粧上相容之載體皆可用於本發明。合適的載體可為含水的 ,或氫化醇,或懸浮之油或其他疏水性物質,Μ提供作為 乳霜,乳液,滋補劑等之共同配方。乳霜是作為本發明局 (請先閱讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐} 31 6 經濟部中央標準局員工消費合作社印製 4 5 0 9 A7 B7五、發明説明() 部治療之較佳者。若需要的話,該載體可Μ只是水,雖然 可能需少量的醇或其他有機溶劑以溶解或分解用於本發明 之少童的疏水性視黃質及腦甙。 若箱要的話*該活性組成成分可配方於化粧上可接受 的氫化醇載體,其具有約40至75重量%的水,較佳55至65 或約60%,及自約25至55重童%,較佳自約25至35或约30 %的陏肪族醇。雖然一些低级脂肪族醇,一元及多元,都 可被使用*乙醇及丙醇是最佳的選擇。許多添加物及補充 物質之納入這類載體,為習知技藝所知是有利的,例如. 高達5%的甘油,較佳1至2%可作爲保濕劑Μ對抗醇的 乾燥效果及增進對滋養物的感覺。安定劑,香料及顔料是 其他添加物的例子。 其他合適的載體包括自約5至約60重量%的疏水性液 體懸浮於一種含水基質的疏水性懸浮體,及水。 若需要的話*可用自0.1至10重量%的鹸性基質*如 含水的氫氧化鈉,精氨酸或三乙醇胺(TEA)而將pH值調至 可接受的範圍。因本發明的剌激皮霜更新的組成物之pH值 對其功效有重大影響 &gt; 適宜的緩衝劑的存在是有利的。任 何這類的緩衝劑及缓衡条統,和齡性基質一起作甩,應作 用而提供介於上述範圍之酸性PH值,而較佳是將pH值維持 於4,5或更低。緩衝劑的量將依其強度而定,但一般自約 0.1至10重量%,較佳約1或2%。一些合適的緩衝劑為 TEiIS(三甲基醇氨基甲烷)緩衝劑及磷酸鹽缓衝劑。 依據本發明的局部施用之結構性皮脂粒治療方法的乳 --------1--^-- (請先閲讀背面之注意事項再填寫本頁) •1Τ 本紙張尺度適用中國國家標準(CNS ) A4規格(210 X 297公釐) 。Λ -32 一 4 6 45 0 9 A7 B7 五、發明説明( 霜為基礎的配方將敘述於下。 審例 #軋霜載體中夕新的三成分;&gt; 皮B旨粒治痗方法 下列的組成成分是依以下的指示混合的(“ Cone η 濃 度及“階段”是橒號組成成分在混合過程中添加之不同階 段): 經濟部中央標準局員工消費合作社印製 組成成分 十六芳基醇(及)ceteareth-20 GMS-PEG 100硬脂酸鹽 PEG-100硬脂酸鹽 油質矽化物 三十碳五嫌 癸酸甘油三酸酯 propylparaben 維他命A棕櫊酸鹽 水 甘油 丁烯乙二醇 carboffier 941 methyl paraben 三乙醇胺 乳酸 腦甙1 &amp; 2 prona1en AC (centerchem) 濃度 2.0 5 6 4 0. 1 1.5 45 5 6 0, 2 0.25 3. 1 8 0.15 5 階段 1 1 1 1 1 1 1 1 2 2 3 4 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家橾準(CNS ) Α4規格(210Χ 297公釐) 33 6 4 45 0 9 A7 B7 五、發明説明() 香料 QS 7 水 QS至 100¾ - 那些習知技藝者熟悉將這些組成成分配方入作爲局部施用 的平滑的乳霜的方法。在80Ϊ:邊混合邊將油層(1)緩慢加 至階段(2)。當所產生的乳濁液開姶形成,加入階段(3)及 詼乳霜變稠。加入下一階段(4)及當乳箱冷至55°C時加入 階段(5-7)。然後邊混合邊冷卻至室溫。 在此實例中,維他命A棕櫊酸鹽,乳酸及腦甙I及I 依本發明明顯地是活性組成成分,而其餘的組成成分構成 乳霜載體。 斩的I?脂粒治療方法夕臨床啻賒 新的皮脂粒治療方法之臨床實驗結果報導於W下之第2表 。治療方法2.1至2. 4M描述於上例的乳箱載體進行,而活 性組成成分及比例報導於該表中。治療方法2.1至2.3及2.5 也許為新的,但是爲了比較之用,且非本發明之較佳實施 例0 I--—II---^ ----II 訂 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度適用中國國家梂準(CNS ) A4規格(210X297公釐) 34 9 〇 5 4 6、 1T This paper size is applicable to China National Standards (CNS) A4 specifications (2 丨 OX297 mm) A 7 B7 Printed by the Ministry of Economic Affairs of the Ministry of Economic Affairs of the People's Republic of China on the consumption cooperation of the staff 5. The invention description () is also another effective The method of destroying the barrier, which increases TEWL by 2 to 10 times, depends on the individual's specific response. Over the course of 8 weeks, this treatment resulted in a positive biological effect consistent with useful sebum treatment. The positive results of this treatment further confirm the broad technical scope of the invention. However, as a commercial method, tape sticking has some disadvantages, including, but not limited to, the response of tape sticking varies widely depending on the carcass, and it is necessary to use expensive laboratory equipment to monitor the function of the barrier. Surfactant exfoliation It has also been found that the use of strong aqueous surfactants daily can damage the barriers for a long time. It is sufficient to use a surfactant such as 10% sodium dodecyl sulfate twice a day. When used alone, SLS is allergic when used for more than 8 weeks. The addition of sphingosine at 0.1% can effectively control and reduce the long-range allergic reaction, so that the treatment method is considered as gentle to sufficient as the practical embodiment of the present invention. It may also include antioxidants and immediate-acting anti-allergic agents, such as kola extract * cerebroside cannot be incorporated into compositions containing sphingosine. If needed * Some of these methods that are effective in increasing TEWL or non-cream treatments can be used with topically administered retinoids and, optionally, a cerebroside cranial box to extend TEWL increase and Peel® repair process. Hop Drops: &gt; Carriers Any cosmetically compatible carrier that is customarily used to deliver Stimulated Skin® Regenerated Acid to the skin * can be used in the present invention. Suitable carriers can be aqueous, or hydrogenated alcohols, or suspended oils or other hydrophobic substances. M provides common formulations as creams, lotions, tonics, and the like. The cream is used as the Bureau of the Invention (please read the notes on the back before filling in this page). The paper size of the book is applicable to the Chinese National Standard (CNS) A4 specification (210X 297 mm) 31 6 Printed by the Consumers Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Preparation 4 5 0 9 A7 B7 V. Invention description (1) The best of the treatment. If necessary, the carrier can only be water, although a small amount of alcohol or other organic solvents may be required to dissolve or decompose. Young children's hydrophobic retinoids and cerebrosides. If required * The active ingredient can be formulated in a cosmetically acceptable hydrogenated alcohol carrier with about 40 to 75% by weight of water, preferably 55 to 65 or About 60%, and from about 25 to 55% by weight, preferably from about 25 to 35 or about 30% of fatty alcohols. Although some lower aliphatic alcohols, both mono- and polyvalent, can be used * ethanol and propylene Alcohol is the best choice. The inclusion of many additives and supplements in this type of carrier is well known in the art, for example. Up to 5% glycerol, preferably 1 to 2% can be used as a humectant. Drying effect and enhance the feeling of nourishment. Materials and pigments are examples of other additives. Other suitable carriers include hydrophobic suspensions from about 5 to about 60% by weight of a hydrophobic liquid suspended in an aqueous matrix, and water. If required * available from 0.1 to 10% by weight % Alkaline base * such as aqueous sodium hydroxide, arginine or triethanolamine (TEA) to adjust the pH to an acceptable range. The pH of the composition renewed by the irritating skin cream of the present invention Efficacy has a significant effect> The presence of a suitable buffer is advantageous. Any such buffer and slow balance system, together with the aging matrix, should act to provide an acidic pH value in the above range, and It is preferred to maintain the pH at 4,5 or lower. The amount of buffering agent will depend on its strength, but generally from about 0.1 to 10% by weight, preferably about 1 or 2%. Some suitable buffering agents are TEiIS (trimethyl alcohol aminomethane) buffering agent and phosphate buffering agent. According to the present invention, a topical structured sebum granule treatment method milk -------- 1-^-(please first Read the notes on the reverse side and fill out this page) • 1T This paper size is applicable to China Standard (CNS) A4 (210 X 297 mm). Λ -32-4 6 45 0 9 A7 B7 V. Description of the invention (Frost-based formula will be described below. Example # Three Ingredients; &gt; Peel B purpose granules treatment method The following ingredients are mixed according to the following instructions ("Cone η concentration and" stage "are different stages of the 橒 component added during the mixing process): Central Ministry of Economic Affairs Cetylaryl (and) cetareth-20 GMS-PEG 100 stearate PEG-100 stearate oleic silicide thirty carbon pentadecanoate triglyceride propylparaben vitamin A palmitate water glycerol butene glycol carboffier 941 methyl paraben triethanolamine lactocerebroside 1 &amp; 2 prona1en AC (centerchem) concentration 2.0 5 6 4 0. 1 1.5 45 5 6 0, 2 0.25 3. 1 8 0.15 5 Stage 1 1 1 1 1 1 1 1 2 2 3 4 (Please read the notes on the back before filling out this page) This paper size is applicable to China National Standard (CNS) Α4 size (210 × 297 mm) 33 6 4 45 0 9 A7 B7 V. Description of the invention () Spice QS 7 Water QS To 100¾-Those skilled in the art are familiar with formulating these ingredients into smooth creams for topical application. At 80Ϊ: slowly add oil layer (1) to stage (2) while mixing. When the resulting emulsion opens, the stage (3) is added and the cream becomes thick. Add the next stage (4) and the stage (5-7) when the milk tank is cooled to 55 ° C. Then cool to room temperature while mixing. In this example, vitamin A palmitate, lactic acid and cerebrosides I and I are obviously active ingredients according to the present invention, while the remaining ingredients constitute a cream carrier. The clinical results of the new sebum granule treatment method are reported in Table 2 below. The treatment methods 2.1 to 2.4M are described in the breast carrier of the above example, and the active components and ratios are reported in the table. The treatment methods 2.1 to 2.3 and 2.5 may be new, but for comparison purposes, and are not the preferred embodiment of the present invention. 0 I --- II --- ^ ---- Order II (Please read the note on the back first) Please fill in this page again) The paper size printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs applies to China National Standard (CNS) A4 (210X297 mm) 34 9 〇 5 4 6

A 五、發明説明() 經濟部中央標隼局員工消費合作社印製 第2表 依本發明之皮脂粒治療方法 治療方法 血流 TEWI TEWL 結實度 大腿 皮膚厚度 皮脂粒 過敏 g/m2/hr 增加S 直徑 2.1) 5¾乳酸 底線 1 2.0? X X X 4.25 1 8週 X 2.33 13 X X X 4 1.5 12週 1.11 2.47 19 27¾ -3¾ 7%(ns) 3.75 1.5 2.2) Μ乳酸 底線 1 2.11 X X X 4.25 1 8週 X 2.69 27 X X X 3.5 1.5 12週 1.07 2.83 34 30》 - Π lOUns) 3 2 2.3) 10UA/UVAP 底線 1 2.03 X X X 4.25 1 8週 X 3.47 71 X X X 3.5 2 12週 1.12 3.67 81 29¾ -5% 8¾ (-4!S) 2,75 2.5 2.4) 10UA/1XVAP /0.5^„GSL 底線 1 1.91 X X X 4.25 1 8週 X 3.87 102 X X X 2.75 2 12週 1.43 6,88 260 43% -11% 10¾(-8¾) 2 2.5 2.5) 每天2x BL!FF PUFF治療 底線 1 2.14 X X X 4.25 1 綱 X 2.39 8 X X X 4 1.5 12週 1.07 2.31 8 6% η ns (ns) 3.75 2 2.6) 每天5-10x 剝落 底線 1 2,14 X X X 4.25 1 8週 X 5.37 151 11% X 6%(ns) 3.75 2.5 12週 1.17 6.07 184 m -8¾ 道(-5¾) 3 3 2.7) 丙嗣浸洗 (每二天一次) 底線 1 2.17 X X X 4 1 8週 1.12 6.92 219 η -3¾ 65:(3υ 3 2.75 12週 X X X X X X X M =底線LA=乳酸VAP=維他命A棕櫊酸鹽GSL=配糖神經鞘脂質ns=不明顯 (請先閲讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家#準(CNS ) A4規格(210X297公釐) 35 464509 經濟部中央標準局員工消費合作社印製 Α7 Β7 五、發明説明() 參照第2表*使用乳酸的治療方法2 . 1及2 . 2得到較大 的TEWL增加,但即使是治療方法2 . 2之為了強烈脫皮作用 之10%乳酸組成物亦只有約33%。需要較高的程度Μ得到 本發明之效果。以維他命Α棕櫊酸鹽加至乳酸之治療方法 2.3顯示在8週時TEWL增加約71%及在12週約81%。雖然 這些TEWL的增加比已知治療方法所得的明顯,發明的障壁 破壊治療方法2.4, 2.6及2.7逹到更高的TEWL之增加,及 自超過100%至高逹260%。過敏程度雖略鳥升高,但仍維 持在可忍受的範圍。 如報導於第1欄的基礎血滾量*對所有治療方法顯示 中度的反應,除了治療方法1.1 (第1表)使用視黃酸而 在12週顯示27%的增加,而更顯箸的是使用依據本發明的 較佳的局部吸收治療方法的治療方法2.4顯示在12週約43 %之更高的基礎血滾置。 關於分级於右手邊倒數第二橘的皮脂粒一般狀況,治 療方法1.2至1.6報導了明顯的改善,治療方法2.1及2.5是 不明顯或非常輕撤。治療方法1.1使用視黃酸而在12週逹 到輕微改善,其顯示降低了一分级點,而治療方法2.2, 2.3,2.4及2.6皆顧示大於一分級黏的改善,而省佳實施 例顯示了超過2値分级點之改善。丙嗣浸洗的治療方法2.7 顯示了 1値分级點的改善Λ證實了本發明的觀念。 為了保障安全,顯亲'了铕床過敏反應之分级。過度過 敏性的治療方法是不被接受的。酋過敏反應分级接近了即 是不利的,如丙嗣浸洗的治療方法|治療方法2 . 7,不令 本纸張尺度適用中國國家標準(CNS ) Α4規格{ 210 X 2们公釐) (請先鬩讀背面之注意事項再填寫本頁) -5 36 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明() 人意外地,在僅8通即顯示2.75的明顯過敏程度,而較佳 的低過敏簧施例之治療方法2.4顙示過敏分级僅2。 乳酸(治療方法2.1及2.2)顯箸改善大腿結實度(近 30% ) *而當包括視黃質(治療方法2.3)時,未見進一 步的改善。依據本發明添加含腦甙之配糖神經鞘脂質(治 療方法2.4)逹到43%之明顯進一步改善,顯示其下組織 之明顯的結構性改善。剝落(治療方法2. 6)顯示較輕微 的改善,而“BUFF-PUFF”及丙酮浸洗(治療方法2.5及2.7 )顯示在結實度上不明顯之改善。 較佳的治療方法2.4明顯地降低大腿直徑,丙詷浸洗 (治療方法2.6)逹到較少之改善,而其他治療方法為不 明顯或僅是輕撤改善。 當治療方法2· 1-2.4及2.6皆顯示在表皮-真皮厚度, 第一個數據,之一些改善,僅有發明的治療方法2.3, 2.4 及2.6顯示降低皮下區域厚度,括弧內數據。在這二項中 ,較佳的治療方法2.4都顙示了實質上最好的结果。 總而言之,報導於第2表的數據顯示發明的治療方法 2.3, 2.4, 2.6及2 ·7提供比比較治療方法大的TEWL之增加 ,及該增加伴隨箸比較治療方法未逹到之血流量及皮虜播 造之改善。治療方法2.4之較佳的發明組成物顯示明顯最 佳的結果,具有顯著的TEWL增加及血流量之大幅度改善及 明顯的大結構性及撤結構性的皮虜及更深層組織之改善。 為了評估徹循環之改善,使用上述的超音波分析來進 行詳細的血流量硏究,結果顯示於下列的第3至第6表。 (請先閲讀背面之注意事項再填寫本頁) 訂 本紙張尺度適用中國國家揉準(CNS &gt; Α4規格(210Χ297公釐} 37 - 五、發明説明() A7 B7 第3表 以雷射doppler轉移測定之撤循環 測試組成物在正常皮虜血流率之效應 在5値値體之結果歸納,在每楠體之前鹫作1〇測量 血流測量 測試組 少於1 介於1和3 介於3和5 介於5和7 &gt;7 之前 3 11 22 10 4 8週後 1 9 20 14 6 16遇後 0 5 21 17 7 剌激劑 0 0 0 3 47 (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 顯示於第3表的血流量測量結果是Μ恣意的相對的數 宇顯示。缌共50分的測量*如表可見,第3表最後一行超 過7的對照剌激劑剌檄血流量佔了 50酤中的47點。自表諛 下來,當期間自最初的讀數進展到以該測試的皮脂粒治療 組成物治療8及16週後,每一組的讀數移向右方。這顯示 測試組成物之施用造成在較高血流量測量之數目之顯箸增 加。 當中間糊(具有數值介於3和5)之血流量讀數之數 目仍大致維持穩定,那些低於3者(於第1及第2欄之測 量數字)至最初的丨4,降至第8週之10,及16週後的5。 參照右手邊的二欄,可見在治療前超過5的測量之數目僅 14,但在8週時增加至20,在16週後增至24。全面而言, 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 38 4 6 4 5 9 Α7 Β7 五、發明説明() 該數目隨箸時間及血流之改善而移至右邊。因此,第3表 顯示該施用的皮脂粒治療組成物能有效地在8週時提供顯 著的血流剌激*及持續施用該治療組成物提供血流量之持 續增加,顯示在16週之進一步的改善。 如所見*第3表的測量是在具有正常、不含皮腊粒的 皮*的個醱之前臂進行的。該數據淸楚地顯示了該局部施 用的組成物之剌激血流量之特性,同時消除了自受皮脂粒 影辔的組織之結構不正常而起的併發症。 第4表 Μ雷射Doppler測定微循環 大腿區域之循環問題 血流率 (請先聞讀背面之注意事項再填寫本頁) 、訂 經濟部中央標準局員工消費合作社印製 在10値個體之結果歸納:所有顯示皮脂粒階段2/3&gt; 在每館値體作30個測量 測試組 少於1 介於1和3 介於3和5 介於5和7 &gt;7 之前 68 133 42 43 14 8週後 45 123 67 52 13 16週後 17 67 128 71 17 對照組-未涉及 6 51 128 110 5 參考數據:對照組平均年紀23.6歲。 使用已知的剌擻劑,如秘魯樹脂,在此方法中增加血流 至10-12。 第4表顯示了在10値具有簌重的皮脂粒,符合上逑的 皮脂粒第2或第3階段搮準,的個體大腿區域總共3ϋ0個 本紙張尺度適用中國國家標準(CNS ) Α4規格(210 X 297公釐) 39 464509 A7 B7五、發明説明() 點之測量結果。底線讀數是在未涉及皮脂粒之皮®區域之 對照組測量。第4表的數據可依第3表相同方式讀取。待 別值得注意的是第1欄的數據,其顯示因其皮脂粒狀況很 大數目的測量區域顯示很差的低於數值1的血滾量,而未 受皮脂粒影饗的組僅有6艏測量低於1。 本發明的測試皮脂粒皮虜組j物之局部施用有效地降 低低於1的測量點的數目,自^台療^的68,至8週的45, 至16週治療後的17。該數目顯週時一般性地向右方 移動*及在16週之進一步移動,顯示在血滾量之持播改善 ,是歸因於所測試的皮脂粒治療組成物之有利功效。 ^^1- ^^^1 1^1 tut n^i i d^i m —^ϋ ^^^1 n^i Λ ,νβ (請先閱讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 本紙張尺度通用中國國家椟準(CNS ) A4規格(2丨0X297公釐) 40 464509 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明() 第5表 以雷射doppl er轉移測定撤循環 大腿區域循環問題 血滾率 個體#1皮脂粒階段2/3 46歲,治療前 1.04 1.22 4.67 4.56 1.11 2.45 0.45 0.56 2.67 0.98 2.22 0.67 0.67 3.55 0.76 0.67 2.19 0.78 2.78 3.67 0.78 3. Π 0.88 2.55 3.56 2.67 3.42 5.6 8.89 5.66 個體#1皮脂粒階段2/3 46歲,16週治療後 1.33 1.92 5.11 5.03 1.44 2.55 1.59 2.56 3,03 1.22 2.78 2.22 3. 12 4.03 1.33 1.87 2.45 1.44 3.11 3.99 1.12 3.84 1.09 2.77 4.03 3.04 4.30 6.15 6.89 5.88 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家橾準(CNS ) A4規格(2丨OX297公釐) -41- /16 0 9 A7 B7 五、發明説明() 第5表報導了該發明的皮脂粒組成物在一個體之效應 之詳細硏究。相對血潦測量報導至2痼明顯的數據。在該 個體的30處進行比較測量,治療前的讓數報導於表的上半 部,治療16週後的讀數於該表的下半部。因此,在表的上 半部之一特定位置的讀數可和表下半部相同位置的讀數比 較,以測定所測試的治療組成物之影嚮,如同“使用前” 及“使用後”之比較。 除了一値例外,所有讀數在治療後都改善了。該例外 是8.89之異常高的讓數。這可能歸因於在鄰近匾域之不良 血滾。所有低於1的讀數都改善至高於1,其中一些改善 非常顯箸。因此在第二欄的第三匍讚數,自治療前的0.67 改善至治療後的2.22。此外,第5表顯示在單一館體之受 皮脂粒影罌的大腿之廣大範圍之血滾的高度明顯的全面改 善,其歸因於該發明治療方法所造成的結構性微循環血管 的改善。 (請先閲讀背面之注意事項再填寫本筲) IV· ,ΐτ 第6表A V. Description of the invention () Printed by the Consumer Cooperatives of the Central Bureau of Standards, Ministry of Economic Affairs, Form 2. The sebum granule treatment method according to the present invention, blood flow TEWI TEWL, firmness, thigh skin thickness, sebum granules, allergy g / m2 / hr, increase S Diameter 2.1) 5¾ lactic acid bottom line 1 2.0? XXX 4.25 1 8 weeks X 2.33 13 XXX 4 1.5 12 weeks 1.11 2.47 19 27 ¾ -3¾ 7% (ns) 3.75 1.5 2.2) lactic acid bottom line 1 2.11 XXX 4.25 1 8 weeks X 2.69 27 XXX 3.5 1.5 12 weeks 1.07 2.83 34 30》-Π lOUns) 3 2 2.3) 10UA / UVAP bottom line 1 2.03 XXX 4.25 1 8 weeks X 3.47 71 XXX 3.5 2 12 weeks 1.12 3.67 81 29¾ -5% 8¾ (-4! S ) 2,75 2.5 2.4) 10UA / 1XVAP /0.5^„GSL bottom line 1 1.91 XXX 4.25 1 8 weeks X 3.87 102 XXX 2.75 2 12 weeks 1.43 6,88 260 43% -11% 10 ¾ (-8 ¾) 2 2.5 2.5) 2x BL! FF PUFF treatment bottom line 1 2.14 XXX 4.25 1 tier X 2.39 8 XXX 4 1.5 12 weeks 1.07 2.31 8 6% η ns (ns) 3.75 2 2.6) 5-10x exfoliation bottom line 1 2,14 XXX 4.25 1 8 weeks X 5.37 151 11% X 6% (ns) 3.75 2.5 12 weeks 1.17 6.07 184 m -8¾ lane (-5¾) 3 3 2.7) Propane dip (once every two days) Bottom line 1 2.17 XXX 4 1 8 weeks 1.12 6.92 219 η -3¾ 65: (3υ 3 2.75 12 weeks XXXXXXXM = bottom line LA = lactic acid VAP = vitamin A palmitate GSL = glycosphingomyelin lipid ns = not obvious (please read the precautions on the back before filling this page ) This paper size applies Chinese National Standard #CNS (A4) (210X297 mm) 35 464509 Printed by the Consumer Cooperatives of the Central Bureau of Standards of the Ministry of Economic Affairs A7 Β7 V. Description of the invention () Refer to Table 2 * Treatment method using lactic acid 2 1 and 2.2 have a large increase in TEWL, but even the 10% lactic acid composition for the strong peeling effect of treatment method 2.2 is only about 33%. A higher degree M is required to obtain the effects of the present invention. Treatment with vitamin A palmitate added to lactic acid 2.3 showed that TEWL increased by about 71% at 8 weeks and about 81% at 12 weeks. Although these TEWL increases are more pronounced than those obtained with known treatments, the invention of the treatment of barrier ruptures increased from 2.4, 2.6, and 2.7 to higher TEWL, and from more than 100% to as high as 260%. Although the level of allergy is slightly higher, it is still tolerable. As reported in column 1, the basal blood volume * showed a moderate response to all treatments, except for treatment 1.1 (Table 1), which showed a 27% increase at 12 weeks using retinoic acid, and more significant Treatment method 2.4, which is a preferred topical absorption treatment method according to the present invention, shows a basal blood roll of about 43% higher at 12 weeks. Regarding the general status of sebum granules classified as the penultimate tangerine on the right hand side, treatments 1.2 to 1.6 reported significant improvements, while treatments 2.1 and 2.5 were not obvious or very easily withdrawn. Treatment 1.1 uses retinoic acid to improve slightly at 12 weeks, which shows a reduction of one grade point, while treatment methods 2.2, 2.3, 2.4, and 2.6 all show improvements greater than one grade of stickiness, and the best embodiment shows Improved by more than 2 値 grade points. The treatment method of dip immersion 2.7 shows an improvement of the 1 値 grading point Λ confirms the concept of the present invention. In order to ensure safety, Xianqin's classification of allergic reactions in the bed. Treatment of hypersensitivity is not acceptable. It is unfavorable to approach the classification of allergic reactions in the U.S., such as the treatment method of immersion of dimethanil | Therapeutic method 2.7, does not make this paper size applicable to the Chinese National Standard (CNS) Α4 specification {210 X 2 mm) ( Please read the precautions on the back before filling out this page) -5 36 A7 B7 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs 5. Description of the Invention () Someone unexpectedly showed a significant degree of allergy at 2.75, The preferred treatment method for the hypoallergenic spring example 2.4 indicates that the allergy grade is only 2. Lactic acid (treatment methods 2.1 and 2.2) significantly improved thigh firmness (approximately 30%) * and when retinoids (treatment method 2.3) were included, no further improvement was seen. According to the present invention, the addition of cerebroside-containing glycosphingomyelin lipids (therapeutic method 2.4) significantly improved to 43%, showing a significant structural improvement of the underlying tissue. Exfoliation (Treatment Method 2.6) showed a slight improvement, while "BUFF-PUFF" and acetone immersion (Treatment Methods 2.5 and 2.7) showed insignificant improvement in firmness. The better treatment 2.4 significantly reduced the diameter of the thighs, and the dip immersion (treatment 2.6) improved less, while the other treatments were not obvious or only slightly improved. When the treatment methods 2.1-2.4 and 2.6 are displayed in the epidermal-dermal thickness, the first data, some improvements, only the invented treatment methods 2.3, 2.4 and 2.6 show a reduction in the thickness of the subcutaneous area, the data in parentheses. In both cases, the preferred treatment 2.4 shows the best results in practice. In summary, the data reported in Table 2 show that the invented treatments 2.3, 2.4, 2.6, and 2 · 7 provide larger increases in TEWL than the comparative treatments, and that the increase is accompanied by a comparison of blood flow and skin loss that were not achieved with the comparative treatments. Improvements made by the prisoner. The better inventive composition of treatment method 2.4 showed significantly better results, with a significant increase in TEWL and a significant improvement in blood flow and a significant improvement in the structure and removal of skin and deeper tissues. In order to evaluate the improvement of the circulation, a detailed blood flow study was performed using the above-mentioned ultrasonic analysis, and the results are shown in Tables 3 to 6 below. (Please read the precautions on the back before filling this page) The size of the paper is applicable to the Chinese national standard (CNS &gt; Α4 size (210 × 297 mm) 37-V. Description of the invention () A7 B7 Table 3 uses laser doppler The effect of withdrawal cycle test composition of the metastatic assay on the normal pelvic blood flow rate is summarized in the 5 carcass, and 10 blood flow measurements were performed before each body. The blood flow measurement test group was less than 1 between 1 and 3 Before 3 and 5 are between 5 and 7 &gt; 7 3 11 22 10 4 8 weeks later 1 9 20 14 6 16 after encountering 0 5 21 17 7 stimulants 0 0 0 3 47 (Please read the notes on the back first (Fill in this page again.) The blood flow measurement results printed and displayed on Table 3 by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs are the relative digital display. 缌 A total of 50 points of measurement * As shown in the table, the last of Table 3 A row of control stimulants with a blood flow of more than 7 accounted for 47 of 50%. From the table, when the period from the initial readings progressed to 8 and 16 weeks after treatment with the test sebum granule composition, The readings for each group move to the right. This shows that the application of the test composition caused The number of volume measurements increased significantly. While the number of blood flow readings in the intermediate paste (with values between 3 and 5) remained roughly stable, those below 3 (measurements in columns 1 and 2) to The initial 4 decreased to 10 in week 8 and 5 after 16 weeks. With reference to the two columns on the right hand side, it can be seen that the number of measurements exceeding 5 before treatment was only 14 but increased to 20 at 8 weeks. After 16 weeks it increased to 24. In general, this paper size applies the Chinese National Standard (CNS) A4 specification (210X297 mm) 38 4 6 4 5 9 Α7 Β7 V. Description of the invention () This number varies with time and blood flow The improvement is shifted to the right. Therefore, Table 3 shows that the applied sebum granule therapeutic composition is effective to provide significant blood flow stimulation at 8 weeks * and continuous administration of the therapeutic composition provides a continuous increase in blood flow, Shows a further improvement at 16 weeks. As seen * Table 3 measurements were taken on the forearm of an individual with normal, wax-free skin *. This data clearly shows the composition of this topical application The nature of the material stimulates blood flow and eliminates self-receiving sebum particles Complications due to the abnormal structure of the shadow tissue. Table 4: Laser Doppler measures the blood flow rate of circulation problems in the microcirculation thigh area (please read the precautions on the back before filling this page), and order the Ministry of Economic Affairs The results printed by the Central Bureau of Standards Consumer Cooperatives in 10 値 individuals are summarized: all show sebum levels 2/3 &gt; 30 measurement test groups in each carcass less than 1 between 1 and 3 between 3 and 5 Before 5 and 7 &gt; 7 68 133 42 43 14 After 8 weeks 45 123 67 52 13 After 16 weeks 17 67 128 71 17 Control group-not involved 6 51 128 110 5 Reference data: The average age of the control group was 23.6 years. Use known tinctures, such as Peruvian resin, to increase blood flow to 10-12 in this method. Table 4 shows the weight of sebum granules at 10 値, which meet the criteria of the second or third stage of the sebum granules of the upper palate, and a total of 3ϋ0 thigh regions. This paper size applies the Chinese National Standard (CNS) Α4 specification ( 210 X 297 mm) 39 464509 A7 B7 V. Measurement results of the () point of the invention. Bottom line readings are taken from a control group in areas of the sebum® that do not involve sebum particles. The data in Table 4 can be read in the same way as in Table 3. It is worth noting that the data in column 1 shows that because of its large amount of sebaceous granules, the measurement area shows poor blood volume below the value of 1, while the group that is not affected by sebaceous granules has only 6艏 Measured below 1. The topical application of the test sebum granules of the present invention to the jelly group effectively reduced the number of measurement points lower than 1, from 68 to 45 for 8 weeks, to 17 for 16 weeks after treatment. This number generally moves to the right * at weekly intervals, and further moves at 16 weeks, which shows that the improvement in blood volume is attributed to the beneficial effects of the sebum granule treatment composition tested. ^^ 1- ^^^ 1 1 ^ 1 tut n ^ iid ^ im — ^ ϋ ^^^ 1 n ^ i Λ, νβ (Please read the precautions on the back before filling this page) Employees of the Central Standards Bureau of the Ministry of Economic Affairs Cooperatives printed this paper in the standard China National Standards (CNS) A4 (2 丨 0X297 mm) 40 464509 Printed by the Consumer Cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs A7 B7 5. Description of the invention () Table 5 uses laser doppl er transfer measurement withdrawal cycle thigh area circulation problem blood roll rate individual # 1 sebum granule stage 2/3 46 years old, before treatment 1.04 1.22 4.67 4.56 1.11 2.45 0.45 0.56 2.67 0.98 2.22 0.67 0.67 3.55 0.76 0.67 2.19 0.78 2.78 3.67 0.78 3. Π 0.88 2.55 3.56 2.67 3.42 5.6 8.89 5.66 Individual # 1 sebum stage 2/3 46 years old, 16 weeks after treatment 1.33 1.92 5.11 5.03 1.44 2.55 1.59 2.56 3,03 1.22 2.78 2.22 3. 12 4.03 1.33 1.87 2.45 1.44 3.11 3.99 1.12 3.84 1.09 2.77 4.03 3.04 4.30 6.15 6.89 5.88 (Please read the notes on the back before filling this page) This paper size is applicable to China National Standard (CNS) A4 size (2 丨 OX297 mm) -41- / 16 0 9 A7 B7 V. Description of the invention () Table 5 reports the composition of the sebum particles invention WH detailed study of the effect of a body. Relative blood radon measurements were reported to 2 痼 apparent data. Comparative measurements were taken at 30 places in this individual. The yield before treatment was reported in the upper half of the table, and the reading after 16 weeks of treatment was in the lower half of the table. Therefore, the reading at a specific position in the upper half of the table can be compared with the reading in the same position in the lower half of the table to determine the effect of the tested therapeutic composition, as in the comparison of "before use" and "after use" . With one exception, all readings improved after treatment. The exception is an unusually high yield of 8.89. This may be due to poor blood flow in the adjacent plaque area. All readings below 1 improved to above 1, and some of the improvements were significant. Therefore, the third praise in the second column improved from 0.67 before treatment to 2.22 after treatment. In addition, Table 5 shows a highly significant and comprehensive improvement in blood rolls over a wide range of thighs affected by sebum grains in a single body due to the improvement of structural microcirculation vessels caused by the treatment method of the present invention. (Please read the notes on the back before filling in this 筲) IV, ΐτ Form 6

經濟部中央標準局員工消費合作杜印製 超音波分析皮虜厚度 10個個體結果之平均,測量每個個體之大腿區域 測試組 表皮/真皮 厚度 表皮/真丧 密度 皮下匾域厚度 皮&quot;f屋域密度 之前 2.34 68% 4.12 33¾ 8週後 2.56 74¾ 3.99 4 η 16週後 3.12 82¾ 3.25 W21 本紙張尺度適用中國國家標準(CNS ) Α4規格(21 ΟΧ29?公釐) 42 經濟部中央標隼局員工消費合作杜印製 Α7 Β7五、發明説明() 第6表顯示在8週之治療後,表皮-直皮皮虜餍厚度 增加及皮下部分減少。二者顧示明顯的密度增加。在施用 組成物16週之治療後,得到進一步的改善。這些數據顯示 本發明組成物提供皮虜狀況之明顯的結構性改善,其能對 皮睹粒狀況產生長程的益處。 τ業應用能力 本發明特別適用於化粧品業Μ提供皮脂粒及皮虜治療 的新配方及方法。 當本發明之說明實施例描逑於上,可了解的各種修正 將是習知技藝者所清楚的。這類修正將涵蓋於本發明之精 神及範畴*而只受限及定義於所附之申請専利範圍。 (請先閱讀背面之注意事項再填寫本買) i -,4Consumption cooperation between employees of the Central Bureau of Standards, Ministry of Economic Affairs, Du printed ultrasound analysis of the average thickness of 10 individuals, and measured the epidermis / dermal thickness epidermis / true density subcutaneous plaque domain thickness of each individual's thigh area test group &quot; f House density before 2.34 68% 4.12 33¾ After 8 weeks 2.56 74¾ 3.99 4 η After 16 weeks 3.12 82¾ 3.25 W21 This paper size applies the Chinese National Standard (CNS) Α4 specification (21 〇 × 29? Mm) 42 Central Bureau of Standards, Ministry of Economic Affairs Employee Consumption Cooperation Du printed Α7 Β7 V. Description of Invention () Table 6 shows that after 8 weeks of treatment, the thickness of the epidermis-straight skin epithelium increases and the subcutaneous part decreases. Both showed a significant increase in density. Further improvement was obtained after 16 weeks of treatment with the composition. These data show that the composition of the present invention provides a significant structural improvement in the condition of the skin, which can provide long-term benefits to the condition of the skin. τ Industry Application Capability The present invention is particularly suitable for the cosmetic industry to provide new formulas and methods for the treatment of sebum granules and pimples. When the illustrative embodiments of the present invention have been described above, various modifications that can be understood will be apparent to those skilled in the art. Such amendments are intended to be within the spirit and scope of the present invention * and are limited and defined only by the scope of the appended claims. (Please read the notes on the back before filling in this purchase) i-, 4

、1T 本紙張尺度適用中國國家榡準(CNS ) Α4規格(2丨Ο X 297公釐) Λ。 -43 -、 1T This paper size is applicable to China National Standard (CNS) Α4 specification (2 丨 〇 X 297 mm) Λ. -43-

Claims (1)

5 4 6 〇 #正 本年月EI 補充9〇H〇 9 〇 5 4 B 4 8888 ABCD 經濟部中夬揉率局負工消費合作社印裝 六、申請專利範圍 第84108866號專利申請案申請專利範圍修正本 修正日期:30年7.月 1. 一種用於改善一皮脂粒狀況的藥學組成物,其係供藉 由連續局部施用至受皮脂粒影響的組織上的皮膚地區 以引發長期高量穿透表皮之水分損失達一段由8週至直 到所要的皮脂粒改善之期間,該組成物包含有,基於 該組成物重量的比例: a) —比例為1至15%之一化粧上可相容之降低阳值 的羥基羧酸以增加穿透表皮之水分損失 (TEWL);及 b) —比例為0.005至約6.0%之一視黃質細胞再生/ 分化調制劑。 2. 如申請專利範圍第1項之藥學組成物’其中該組成物 在8週的持績施用後,該TEWL至少增加100%。 3. 如申請專利範圍第1項之藥學組成物,其中該組成物 之持績施用係要被持續另外4週》 4. 如申請專利範圍第1項之藥學組成物,其中該組成物 能有效地增加TEWL至少100%,而其施用之期間為至 少自8週至26週。 5. 如申請專利範圍第1項之藥學组成物,其進一步包含 有: c) 一比例為0.01至5%之腦甙障壁修復抑制劑,俾以 抑制皮膚水障壁之修復。 6. 如申請專利範圍第5項之藥學組成物,其中該組成物係 本紙張尺度逋用令國國家橾準(CNS M4規格(2丨0 X 297公釐) ι^ϋ ml In, ^^^^1 -- - - n^i i4n 1^1^h. (請先s讀背面之注意事項再填寫本頁) Λ8 B8 C8 D8 經濟部中夬標準局貝工消资合作社印«. 六、申請專利範圍 要供每天局部施用二次達至少8週。 7,如申請專利範圍第1項之藥學組成物,其中該組成物 包含有5至10%的乳酸、乙醇酸或水楊酸,〇 3至3.0%的 維他命A棕櫚酸鹽,以及〇.1至0.5%之一腦甙物質。 8. 如申請專利範圍第1項之藥學組成物,其中該組成物 可被應用於一擇自於下列群中的水障壁破壞治療:施 用溶液中之脫皮劑’機械磨擦,以及疏水性皮膚障壁 成分之溶劑萃取物。 9. 一種在皮脂粒治療上供每日局部施用至受皮脂粒影響 的皮膚區域上之藥學組成物,該組成物在8週之局部施 用後能有效增加TEWL至少100%,該組成物包含有, 以基於該组成物重量之比例: a) —比例為1至15%之一化粧上可相容之降低pH值 的羥基羧酸以增加穿透表皮之水分損失 (TEWL);及 b) —比例為0.005至約6.0%之一視黃質細胞再生/ 分化調制劑。 c) 一比例為0.01至5%之腦甙障壁修復抑勉劑,俾以 抑制皮膚水障壁之修復。 10·如申請專利範圍第9項之藥學組成物,其包含有5至10% 的乳酸、乙醇酸或水楊酸,0.3至3.0%的維他命A棕櫚 酸鹽,以及0.1至0.5%之一腦甙物質。 ‘ 11.如申請專利範圍第10項之藥學組成物,其包含有至少 一種擇自於下列之選擇性成分:用以刺激血流之利尿 ---------裝-----_—訂------線 (請先閱讀背面之注意事項异心寫本頁) 本纸張尺度逍用中國國家橾準(CNS ) Λ4洗格(2丨〇Χ 297公釐) 5 4:, 6 9 ο ABCD 經濟部中央揉準局員工消费合作社印製 六、申請專利範圍 劑、用以控制由該TEWL增加劑或該細胞再生/分化調 制劑所引起的過敏反應之抗過敏劑及抗氧化劑,以及 此等之混合物。 12. —種用於皮脂粒治療上之藥學組成物,其包含有一有 效量之一 TEWL增加劑、一皮膚細胞分化調制劑以及一 用以抑制皮膚之水障壁修復的障壁修復抑制劑。 13. 如申請專利範圍第12項之藥學組成物,其包含有,基 於該組成物之重量,一比例為1至15重量%之該TEWL 增加劑。 14. 如申請專利範圍第13項之藥學組成物,其特徵為該 TEWL增加劑之比例係為自5至10%,而該TEWL增加劑 是乳酸、水楊酸或乙醇酸。 15. 如申請專利範圍第12項之藥學組成物,其特徵為該細 胞再生/分化調制劑是呈一比例為自0.005至6.0重量% 之視黃質。 16. 如申請專利範圍第13項之藥學組成物,其特徵為該障 壁修復抑制劑是呈一比例為自0.01至5.0重量%之一腦 甙。 17. 如申請專利範圍第12項之藥學組成物,其特徵為包含 有至少一種擇自於下列之選擇性成分:用以刺激血流 之利尿劑、用以控制由該TEWL增加劑或該細胞再生/ 分化調制劑所引起的過敏反應之抗過敏劑及抗氡化 劑,以及此等之混合物。 18·如申請專利範圍第12項之藥學紕成物,其特徵為包含 -3- 本紙張尺度適用令國國家樣準(CNS ) A4規格(210 X 297公趁! ' ' , ( ^ 訂* I I 線 (請先閲讀背面之注意事項^·ν寫本頁) 經濟部中央橾準局員工消費合作社印装 46 45 0 9 Α8 B8 C8 _____D8 六、申請專利範圍 有自5至10%的乳酸,自0.5至4.0%維他命A標糊酸鹽及 自0.1至0.5%的腦甙。 19. 如申請專利範圍第12項之藥學组成物,其特徵為在8週 的持續施用後,其能有效地增加TEWL至少100%。 20. —種用以製備在皮脂粒治療上用於每曰局部施用至受 皮脂粒影響的皮膚區域上之藥學組成物之方法,該組 成物在8週之局部施用後能有效地增加TEWL至少 1 〇〇%,該方法之特徵為包括,基於該組成物的重量之 比例來摻合下列組份: a) —比例為1至15%之一化粧上可相容之降低pH值 的羥基羧酸以增加穿透表皮之水分損失 (TEWL);及 b) —比例為0·005至約6·0%之一視黃質細胞再生/ 分化調制劑 c) 一比例為0.01至5%之腦甙障壁修復抑制劑,俾以 抑制皮膚水障壁之修復。 21. 如申請專利範圍第20項之方法,其特徵為該組成物包 含有自5至10%的乳酸、乙醇酸或水楊酸,自0.3至3.0% 的維他命Α棕櫚酸鹽及自0.1至0.5%的腦甙物質。 22. 如申請專利範圍第21項之方法,其特徵為該組成物包 含有至少一種擇自於下列之選擇性成分:用以刺激血 流之利尿劑、用以控制由該TEWL增加劑或該細胞再生 /分化調’制劑所引起的過敏反應之抗過敏劑及抗氧化 劑,以及此等之混合物。 -4- 本紙浪尺度適用t國國家ϋ( CNS ) A4規格(210X297公釐) ---------^-------ir‘------線’ (請先聞讀背面之注意事項再填寫本瓦) 464509 Α8 Β8 C8 D8 經濟部中央標準局員工消費合作杜印裝 六、申請專利範圍 23. —種用以製備用在皮脂粒治療上之藥學組成物之方 法’其特徵為包括摻合有效量之一TEWL增加劑、一皮 膚細胞分化調制劑以及一用以抑制皮膚的水障壁之修 復的障壁修複抑制劑。 24. 如申請專利範圍第23項之方法,其特徵為該組成物包 含有’基於該組合物之重量,一比例為自1至丨5重量% 之TEWL增加劑。 25. 如申請專利範圍第24項之方法,其特徵為該TEWL增加 劑之比例為自5至10%,而該TEWL增加劑是乳酸、水 揚酸或乙醇酸。 26. 如申請專利範圍第23項之方法,其特徵為該細胞再生 /分化調制劑是呈一比例為自0.005至6.0重量%之視黃 質a 27. 如申請專利範圍第23項之方法,其特徵為該障壁修復 抑制劑是呈一比例為自0.01至5,0重量%之一腦武。 28·如申請專利範圍第23項之方法,其特徵為該組成物包 含有至少一種擇自於下列之選擇性成分:用以刺激血 流之利尿劑' 用以控制由該TEWL增加劑或該細胞再生 /分化調制劑所引起的過敏反應之抗過敏劑及抗氧化 劑,以及此等之混合物·» 29. 如申請專利範圍第23項之方法,其特徵為該組成物包 含有自5至1 0°/。的乳酸’自0·5至4.0%的維他命A棕櫊酸 鹽,及自0.1至0.5%的腦甙。 30. 如申請專利範圍第23項之方法,其特徵為在8週的持續 施用後,該組成物能有效雎増加TEWL至少100%。 本紙張尺度逋用中國固家標準(CNS ) Μ说格(2ίΟΧ 297公缝) - --I - - - - - 1— I. nn a^— nn ^1.^1 '一eJ (請先聞讀背面之注意事項再填寫本頁) 修正 公告 本年月曰 申請曰期 η. 1火 案 號 一1 — tit “S ί‘ 類 別 k έί K Va 以上各欄由本局填柱) A4 C4 464509 第84108866號 發明 專利説明書 修正頁 修正日期:印年^ 中 文 用於改善一皮脂粒狀浞的藥學組成物 稱 英 文 a pharmaceutical composition for ameliorating a cellulite condition 姓 名 國 藉 華爾德P.史密斯 美國 裝 發明 住、居所 美國康乃狄克州新卡那安市瓦克受路46號 訂 姓 名 (名稱) 美商*玫琳飢化粧品股份有限公司 經濟部t央梂隼局貝工消费合作社印装 線 國 箱· 美國 申請人 住、居所 (事務所) 代表人 姓 名 美國德州逹拉斯市史坦蒙高速公路8787號 羅傑*保加杜趼 本紙張尺度通用中國®家襟準(CNS ) A4規格(21〇x297公釐) A7 B7. 經步-部中央標準局員J-消费合作社印取 464509 五、發明説明(i ) 本發明係有關局部施用的皮脂粒治療,包括組成物及 方法,其長期使用時,如每天施用而達數個月之久,可產 生皮脂粒狀況之結構性改善。皮脂粒一詞是指在皮膚下大 量脂肪細胞不正常的聚集|而造成皮膚表面的難看之局部 之視覺不連續性。 皮脂粒是Nicole Ronsard於1970年代創造的名詞(見 Webster's New Universal Unabridged Dictionary,第 二版,Dorset Baber i983 )是於描述非正常脂肪塊狀之 不正常的皮下蓄積而造成皮膚正常之平滑曲線之不雅觀之 阻隔之廣泛現象。 生理上而言,皮脂粒是因身體易發生脂肪蓄積部位的 微循環之退化。嚴重的皮脂粒之特徵爲皮下血管的退化, 血流不良,皮膚表皮及真皮層之變薄,在皮下區域由蛋白 質包圍之脂肪物質之硬塊之出現,及體液之蓄積之貯存。 結果造成皮膚“橘皮”般的外觀。 皮脂粒最常在大腿,臀部及上臂造成問題,較少在外 肢,背部,軀幹及胴體中央,及在臉,頸,手及足上通常 不明顯。皮脂粒通常和肥胖有關,但也出現在正常或近乎 正常體重的個人的皮膚上。在女性比在男性上較常見,亦較 在白種人比在較深膚色的個人身上較常出現。 因嚴重損害個人的外觀,皮膚粒具有深遠的心理影響 ,傷害到受影響個人的自尊及不利於青年男女的健康心理 發展。因此,非常需要有效的皮脂粒治療方法。 已知治療皮脂粒的方法包括局部的機械作用,局部施 本紙浪尺度通用中囷國家標率(ΓΝ5 ) Λ4規格(210X297公漦) (請先閱讀背面之注項再填湾本頁) *1T ^ 經满部中央標率局肩工消費合作社印製 5 45 0 9 a? __B7 ...................^ 五、發明説明(3 ) 咖啡因I茶葉鹼及其他黃嘌呤類,在高濃度時似乎在 作爲利尿劑及在促進脂肪代謝上有效。氨茶鹼,目前是已 I i 知的大腿部乳霜或大腿平滑乳霜之受歡迎的活性成分,似 乎在作爲促進淋巴液排出之強利尿劑上有效,但據報具有 明顯的毒性副作用(見Merck Index第11版,Merck &amp; Co. Inc. 1989專題論文第477號)。這些藥劑並未考慮皮膚及 血管的結構性缺陷。 Trebosc等人的美國專利第5,030,451號敘述了包含改 良的咖啡因衍生物作爲活性劑之一些化粧組成物。依據 Trebosc等人之第9欄第15-20行,該公開的配方具有 “良好及長效的‘分解脂肪之性質’及因而證明在瘦 身計畫及治療皮脂粒上非常有效。&quot; 然而,並未報導有效的數據。在第1欄第61-65行&gt; Trebosc等人傳授了皮下穿透之較快的速率而確認了這些 藥劑在治療皮脂粒上的優越性。 Mausner美國專利第5,21 5,759號參考了使用甲基矽烷 醇茶葉鹼醋酸鹽藻朊酸鹽及甲基矽烷醇甘露糖醛酸鹽供作 防皮脂粒之活動。缺乏說明性之公開,這類物質作用被假 設是等於利尿劑。 推銷刺激物組成物(含咖啡因,氨茶鹼或相關的藥劑 作爲活性組成成分)給消費者用於治療皮脂粒之一個缺點 是用藥方面的問題將阻止其被包括於藥局即可銷售之化粧 品組成物。長期的重複使用也許會引發有害之副作用,而 政府的管制規定會限制市場行銷性。另一個缺點是這類藥 _____ _ 6&quot; . _ 本紙張尺度適用中國國家標坪_ ( CNS ) Μ規格(2ΙΟΧ:297公漦} (請先閲讀背面之注意事項再填寫本頁) ,1Τ 4 5 45 0 9 A7 B7 Llti 經淖部肀央栋準局員工消費合作社印聚 五、發明説明( 劑未考慮皮膚及血管缺陷之結構問題。 磨砂顆粒機械作用,磨去治療的外層,平滑治療表面 t t 及刺激治療更新,但未能促進淋巴液排出,長期的微循環 退化或脂肪代謝。磨砂顆粒^硬的顆粒,一般爲懸浮乳霜 或膠,其在治療上磨擦或按摩而達到機械剝落的作用。該 顆粒通常是聚乙烯球,然而天然粒子如壓碎的桃或杏核亦 曾被使用。這些產品進一歩的缺點是很難控制過敏問題。 局部施用的視黃質,例如Kligman之美國專利第 5,051 ,449號,能有限度地改善皮脂粒。Kligman公布了在 超過6個月局部施用視黃酸配方後,和一未指名之非藥用 乳霜之比較功效之定性報告。所述的功效包括皮膚增厚, 新血管數目之增加,及使用捏挾測試(第6欄,第50-61 行)之可觀察到之中度至明顯之改善。因未提供任何定量 數據,因而習知技藝者無法判定Kligman之皮脂粒治療之 教導之價値。 許多人希望及預期皮脂粒治療方法在6個月治療之後 比中度改善更具功效。必須限制所施用的視黃酸濃度以避 免過敏(見Kligman第2欄,第59-60行),因而無法藉由 增加劑量而達到足夠的功效•視黃酸治療方法並未提供對 皮脂粒令人滿意的長期治療,及需要更有效的局部施用的 治療方法。相反於Kligman之未具根據之歸納,我在定量 臨床硏究發現在每天治療達3個月後,視黃酸並未造成明 顯的皮虜增厚作用。因此,需要一種容易施用的皮脂治療 方法,而其能在合理的時間內提供結構性改善。 本纸张尺度適州中國囤家椟净.((::呢)/\4規格(210&gt;:297公麓) (請先閲请背面之注意事項再填寫本頁) ,1T A7 B7 J6 45 Ο 9 五、發明説明( 本發明,如所申請專利,是要提供一種治療方法。其 解決提供比以前所得方法更具效力之可對消費者行銷之容 易施用的局部皮脂粒治療方法之問題,及其能在合理時間 內造成明顯的結構性改善。本發明也解決了提供當持續長 期使用時能產生漸進性,結構性改善的局部性皮脂粒治療 方法之問題,較佳的實施例促進身體受皮脂粒影響部位的 皮膚之明顯增厚及增進組織之結實,減少大腿腿圍,及增 加微循環血流。 本發明藉由提供皮脂粒治療方法而解決上述問題,該 方法在受皮脂粒影響的組織破壞該部位皮膚的水障壁特性 一段長時間使足以激發治療的更新及血管之再生而達到增 強之功效。 長期的破壞皮膚障壁是有困難的。當然地,該破壞方 法不能強至傷害皮膚之敏感的真皮層,或造成疼痛或顯著 的過敏。但爲得本發明之功效,該治療應提供持久的破壞 障壁的作用,而非暫時性的效果。因爲障壁的正常作用對 生存是必要的,破壞該障壁會引起自然的反應而快速修補 該障壁。更詳細地,在延長治療期間之數週內,如8週或 更長,障壁作用要持續被破壞 穿透表皮的水分損失之增加可用來監測障壁作用。治 療12週後測量TEWL,最後治療之後至少8小時測量,發現 除了視黃質之外的已知的皮脂粒治療方法具有很少的對障 壁作用之持續的影響,有些似乎降低TEWL。視黃酸,一種 脫皮劑,及至少另一種剝落劑,在12週時只顯示TEWL輕微 本紙张尺度適用中國國家標卒((:NS ) Λ4規格UIOX 297公赘) (請先閲讀背面之注意事項再填寫本頁) '1Τ 經滅部中火標準局貝工消f合作社印製 A7 B7 五 經濟部中央棉準局負工消贽合作社印Μ 464509 、發明说明(8 ) 皮膚水分損失。一般該治療是每天施用一或二次。 許多新的皮脂粒治療方法包括皮膚的各種局部機械治療, J 如磨砂,粗化或萃提或溶劑萃取治療,二種治療方法都是劇烈 或急進地施用使能如上述提昇TEWL 100%或更多及維持一段長 時間。然而,較佳的治療方法包括能局部施用的一種化學組成 物,較佳是柔化劑或乳霜形式,及以每天不超過一或二次施用 的頻率而能維持增加的TEWL程度。 淸楚地,須控制本發明之治療方法之急遽性以使其能 在數週或數月之期間被接受,而不致造成嚴重或痛楚的過 敏,變紅’脫皮或過度的不適。然而,許多人可容忍這些 症狀之短期出現。 本發明另一方面提供了一種皮脂粒組成物,其包括能 立即或短期增加TEWL之TEWL增加劑及其作用爲維持增加的 TEWL程度的障壁破壞劑。較佳地,該組成物也包括皮膚脂質 口成抑制劑,以預防水障壁之過早重建及加強該組成物之皮 脂粒治療功效。 本發明此方面之較佳實施例中,該TEWlJf加劑是化粧上 相容的,降低pH値的羥基羧酸,較佳具有剝落劑的性質,及 至少中度可溶於水或氫化醇中使能包含於化粧組成物中。這 類的酸包括α-羥基羧酸,特別是例如乳酸及乙醇酸,及其 他羥基羧酸,如2-羥基本酸,特別是水楊酸。這些酸之有效 性似乎和其能降低皮膚之細胞間液之邱値的能力有關。所使 用的酸及其濃度之選擇是爲了達到所要的TEWL之增加而不造 成過度之過敏。 (請先閱请背面之注意事項再填寫本頁) 訂 -11 - 修正太A 3日| 4 6 4 5 0 9 本年a H A5 補充 90. 7. 20 B5 四、中文發明摘要(發明之名稱: 用於改善一皮脂粒狀況的藥學組成物 藉由比較數瘅顯示新的局部施用的皮脂粒治療在受皮 脂粒影堪的大腿部位組继之结構性改巻,包括皮慮增厚, 大腿结贾化及大腿部縮小。所公開的治療方法瓦解皮盧封 水的陣壁及提高穿透表皮之水分損失(TEWL)長逹數遇或數 値月,及包括機械或溶劑作用如帶解析或丙酮沖洗。較佳 的洽療方法使用乳霜,其含有活性組成成分如乳酸以提高 TEWL* —種視黃霣*較佳是維他命A棕櫊酸鹽,以瓦解障 壁之建立及延長TEWL之增加,及一種腦甙以抑制脂質的合 成及加強TEWL之增加。利尿劑,為了立即的美観之進展, 抗過敏剤及抗氧化劑以控制遇敏反應,是其他可添加之组 成成分。 英丈發明摘要(發明之名稱:a pharmaceutical composition for ameliorating a cellulite condition 經涛部中夬橾隼局貝工消费合作社印«. ---------I l 裝 I (請先閲讀背面之注意事項再填寫本頁各梱) IT 線 New topically applied treatments for cellulite are shown by ^ comparative data to effect structural improvements in cellulite-afflicted thigh area tissues including skinthickening, thigh-firming and thigh-reduction. The disclosed treatments disrupt the skints water barrier and elevate trans-epideriaal water loss (TEWL) for extended periods of weeks or months and include methods of mechanical; or solvent action, for example, tape stripping, or acetone-washes .Preferred treatments use creams with active ingredients such as lactic acid to elevate TEWL, a retinoid,! preferably vitamin A palmitate to disrupt barrier rebuildingj and prolong elevation of TEWL levels, and a cerebroside to 丨 inhibit lipid synthesis and intensify.the TEWL elevation. Diuretics, for immediate esthetic improvements; anti-irritants and anti-oxidants for irritation control are optional ingredients , 本紙ft尺度遑用t國國家梯孪(CNS ) A4洗格(2丨0X 297公釐) 5 4 6 〇 #正 本年月EI 補充9〇H〇 9 〇 5 4 B 4 8888 ABCD 經濟部中夬揉率局負工消費合作社印裝 六、申請專利範圍 第84108866號專利申請案申請專利範圍修正本 修正日期:30年7.月 1. 一種用於改善一皮脂粒狀況的藥學組成物,其係供藉 由連續局部施用至受皮脂粒影響的組織上的皮膚地區 以引發長期高量穿透表皮之水分損失達一段由8週至直 到所要的皮脂粒改善之期間,該組成物包含有,基於 該組成物重量的比例: a) —比例為1至15%之一化粧上可相容之降低阳值 的羥基羧酸以增加穿透表皮之水分損失 (TEWL);及 b) —比例為0.005至約6.0%之一視黃質細胞再生/ 分化調制劑。 2. 如申請專利範圍第1項之藥學組成物’其中該組成物 在8週的持績施用後,該TEWL至少增加100%。 3. 如申請專利範圍第1項之藥學組成物,其中該組成物 之持績施用係要被持續另外4週》 4. 如申請專利範圍第1項之藥學組成物,其中該組成物 能有效地增加TEWL至少100%,而其施用之期間為至 少自8週至26週。 5. 如申請專利範圍第1項之藥學组成物,其進一步包含 有: c) 一比例為0.01至5%之腦甙障壁修復抑制劑,俾以 抑制皮膚水障壁之修復。 6. 如申請專利範圍第5項之藥學組成物,其中該組成物係 本紙張尺度逋用令國國家橾準(CNS M4規格(2丨0 X 297公釐) ι^ϋ ml In, ^^^^1 -- - - n^i i4n 1^1^h. (請先s讀背面之注意事項再填寫本頁)5 4 6 〇 # The original month EI supplement 9〇〇〇 〇5 4 B 4 8888 ABCD Printed by the Ministry of Economic Affairs Bureau of the Ministry of Economic Affairs and Consumer Cooperatives 6. Application for Patent Scope No. 84108866 Patent Application for Amendment of Patent Scope Date of this amendment: July 30th 1. A pharmaceutical composition for improving the condition of sebum granules, which is intended to cause long-term high-volume penetration by continuous topical application to the skin area on tissues affected by sebum granules Epidermal water loss for a period from 8 weeks to the desired improvement of sebum particles, the composition contains, based on the weight of the composition: a)-a cosmetically compatible reduction of 1 to 15% Positive hydroxycarboxylic acids to increase water loss through the epidermis (TEWL); and b)-a retinoid cell regeneration / differentiation modulator with a ratio of 0.005 to about 6.0%. 2. The pharmaceutical composition according to item 1 of the patent application, wherein the TEWL is increased by at least 100% after 8 weeks of sustained application. 3. For example, if you apply for a pharmaceutical composition in the scope of the first item of the patent, the performance application of the composition is to be continued for another 4 weeks "4. If you apply for a pharmaceutical composition in the scope of the first item of the patent, the composition is effective Increase TEWL by at least 100%, and its application period is from at least 8 weeks to 26 weeks. 5. The pharmaceutical composition according to item 1 of the patent application scope, further comprising: c) a cerebroside barrier repair inhibitor at a ratio of 0.01 to 5% to prevent the repair of the skin water barrier. 6. For example, the pharmaceutical composition in the scope of application for patent No. 5 wherein the composition is in accordance with the national standard of the paper (CNS M4 specification (2 丨 0 X 297 mm)) ι ^ ϋ ml In, ^^ ^^ 1---n ^ i i4n 1 ^ 1 ^ h. (Please read the precautions on the back before filling out this page) Λ8 B8 C8 D8 Printed by the China Industrial Standards Bureau of the Ministry of Economic Affairs, China Industrial Standards Co., Ltd. «. 6 2. The scope of patent application shall be for topical application twice a day for at least 8 weeks. 7. The pharmaceutical composition of item 1 of the scope of patent application, wherein the composition contains 5 to 10% lactic acid, glycolic acid or salicylic acid, 0 to 3.0% of vitamin A palmitate, and one to 0.1% to 0.5% of a cerebroside substance. 8. For example, the pharmaceutical composition of the first scope of the application for a patent, wherein the composition can be applied to a selective Treatment of water barrier destruction in the following groups: peeling agent 'mechanical friction in application solutions, and solvent extracts of hydrophobic skin barrier ingredients. 9. A daily topical application on sebum granules to those affected by sebum granules A pharmaceutical composition on the skin area that effectively increases TEWL after 8 weeks of topical application 100% less, the composition contains, based on the proportion of the weight of the composition: a)-a ratio of 1 to 15% of cosmetically compatible pH-lowering hydroxycarboxylic acid to increase the moisture that penetrates the epidermis Loss (TEWL); and b)-one of retinoid cell regeneration / differentiation modulators at a ratio of 0.005 to about 6.0%. c) A cerebroside barrier repair inhibitor with a ratio of 0.01 to 5%, to inhibit the repair of skin water barrier. 10. The pharmaceutical composition according to item 9 of the patent application scope, which contains 5 to 10% of lactic acid, glycolic acid or salicylic acid, 0.3 to 3.0% of vitamin A palmitate, and 0.1 to 0.5% of one brain. Glycoside substances. '11. The pharmaceutical composition according to item 10 of the patent application scope, which comprises at least one optional ingredient selected from the group consisting of: a diuretic for stimulating blood flow ----------------- -_— Order ------ line (please read the precautions on the back to write this page) The paper size is in accordance with the Chinese National Standards (CNS) Λ4 wash case (2 丨 〇 × 297 mm) 5 4 :, 6 9 ο Printed by ABCD Central Consumer Bureau of the Ministry of Economic Affairs, Consumer Cooperatives 6. Application for patent scope agents, anti-allergic agents to control allergic reactions caused by the TEWL increasing agent or the cell regeneration / differentiation modulator And antioxidants, and mixtures of these. 12. A pharmaceutical composition for the treatment of sebum granules, comprising a TEWL increasing agent in an effective amount, a skin cell differentiation modulator, and a barrier repair inhibitor for inhibiting water barrier repair of the skin. 13. The pharmaceutical composition according to item 12 of the patent application scope, which comprises the TEWL increasing agent in a proportion of 1 to 15% by weight based on the weight of the composition. 14. The pharmaceutical composition according to item 13 of the application, characterized in that the proportion of the TEWL increasing agent is from 5 to 10%, and the TEWL increasing agent is lactic acid, salicylic acid or glycolic acid. 15. The pharmaceutical composition according to item 12 of the patent application, characterized in that the cell regeneration / differentiation modulator is a retinoid in a proportion from 0.005 to 6.0% by weight. 16. The pharmaceutical composition according to claim 13 of the application, characterized in that the barrier repair inhibitor is a cerebroside in a proportion of from 0.01 to 5.0% by weight. 17. The pharmaceutical composition according to item 12 of the patent application, characterized in that it contains at least one optional ingredient selected from the group consisting of a diuretic for stimulating blood flow, a control for the TEWL increasing agent or the cell Antiallergic and antihypertensive agents for allergic reactions caused by regeneration / differentiation modulators, and mixtures thereof. 18 · If the pharmaceutical product of item 12 of the patent application scope is characterized by including -3- this paper size is applicable to the national standard (CNS) A4 specification (210 X 297)! '', (^ Order * Line II (please read the notes on the back ^ · ν first write this page) Printed by the Consumer Cooperatives of the Central Government Bureau of the Ministry of Economic Affairs 46 45 0 9 Α8 B8 C8 _____D8 6. The scope of patent application is from 5 to 10% lactic acid. From 0.5 to 4.0% of vitamin A standard glutamate and from 0.1 to 0.5% of cerebroside. 19. The pharmaceutical composition according to item 12 of the patent application is characterized in that it is effective after 8 weeks of continuous administration Increasing TEWL by at least 100%. 20. A method for the preparation of a pharmaceutical composition for topical application to sebaceous granules affected skin areas in the treatment of sebum granules, the composition being administered topically after 8 weeks It can effectively increase TEWL by at least 100%, and the method is characterized by including the following components based on the weight ratio of the composition: a)-a cosmetically compatible ratio of 1 to 15% Lowering the pH of hydroxycarboxylic acids to increase water loss through the epidermis (TEWL); and b) -One of the retinoid cell regeneration / differentiation modulators at a ratio of 0.005 to about 6.0% c) A cerebroside barrier repair inhibitor at a ratio of 0.01 to 5% to prevent the repair of skin water barriers. 21. The method as claimed in claim 20, characterized in that the composition contains from 5 to 10% of lactic acid, glycolic acid or salicylic acid, from 0.3 to 3.0% of vitamin A palmitate and from 0.1 to 0.5% of cerebroside substance. 22. The method of claim 21, wherein the composition contains at least one optional ingredient selected from the group consisting of a diuretic for stimulating blood flow, a control for the TEWL increasing agent, or the Anti-allergic agents and antioxidants for allergic reactions caused by cell regeneration / differentiation formulations, and mixtures thereof. -4- The size of this paper is applicable to the country's national standard (CNS) A4 (210X297 mm) --------- ^ ------- ir '------ line' (Please First read the precautions on the back before filling in this tile) 464509 Α8 Β8 C8 D8 Consumer cooperation of the Central Standards Bureau of the Ministry of Economic Affairs Du Yinzhang 6. Application for patent scope 23. —A pharmaceutical composition for the preparation of sebum granules The method is characterized by including an effective amount of a TEWL increasing agent, a skin cell differentiation modulator, and a barrier repair inhibitor for inhibiting the repair of the water barrier of the skin. 24. The method according to item 23 of the patent application, characterized in that the composition contains a TEWL increasing agent in a proportion of from 1 to 5 wt% based on the weight of the composition. 25. The method of claim 24, characterized in that the proportion of the TEWL increasing agent is from 5 to 10%, and the TEWL increasing agent is lactic acid, salicylic acid or glycolic acid. 26. The method according to item 23 of the patent application, characterized in that the cell regeneration / differentiation modulator is a retinoid in a proportion from 0.005 to 6.0% by weight. 27. The method according to item 23 of the patent application, It is characterized in that the barrier repair inhibitor is a brain force in a ratio of from 0.01 to 5, 0% by weight. 28. The method according to item 23 of the patent application, characterized in that the composition contains at least one optional ingredient selected from the group consisting of: a diuretic for stimulating blood flow 'to control the TEWL increasing agent or the Antiallergic agents and antioxidants for allergic reactions caused by cell regeneration / differentiation modulators, and mixtures thereof »29. The method according to item 23 of the patent application, characterized in that the composition contains from 5 to 1 0 ° /. Lactic acid 'from 0.5 to 4.0% of vitamin A palmitate and from 0.1 to 0.5% of cerebroside. 30. The method of claim 23, wherein the composition is effective to increase TEWL by at least 100% after 8 weeks of continuous application. The dimensions of this paper are in accordance with Chinese Goods Standards (CNS), M Grid (2ίΟΧ 297 stitches)---I-----1— I. nn a ^ — nn ^ 1. ^ 1 '一 eJ (Please first Please read the notes on the back of the page and fill in this page again) Amendment Notice This month, the application date η. 1 fire case No. 1 — tit "S ί 'category k έί K Va The above columns are filled by this bureau) A4 C4 464509 No. 84108866 Amendment page of the invention patent specification Date of amendment: Year of printing ^ Chinese pharmaceutical composition for ameliorating a cellulite condition is called English a pharmaceutical composition for ameliorating a cellulite condition Residence, Residence Name: (Name), No. 46, Wacker Road, New Kanana, Connecticut, U.S. Boxes · U.S. Applicant's Residence, Domicile (Office) Representative Name Roger * Burgadou, 8787 Steinmon Highway, Milas, Texas, USA Paper Size GM China® Flap (CNS) A4 specification (21 × 297 mm) A7 B7. Step-Ministry of Central Standards Bureau, J-Consumer Cooperative, printed 464509 5. Description of the invention (i) The present invention relates to the topical application of sebum granules, including the composition And method, when it is used for a long time, if it is applied daily for several months, it can produce a structural improvement in the condition of sebum particles. The term sebum particles refers to the abnormal accumulation of a large number of fat cells under the skin | The unsightly part of the visual discontinuity. Sebum is a term coined by Nicole Ronsard in the 1970s (see Webster's New Universal Unabridged Dictionary, 2nd edition, Dorset Baber i983) to describe the abnormal subcutaneous fat mass. Accumulation causes a wide range of unsightly barriers to the normal smooth curve of the skin. Physiologically speaking, sebaceous granules are caused by the microcirculation of fat accumulation sites in the body. Serious sebaceous granules are characterized by the degradation of subcutaneous blood vessels, Poor blood flow, thinning of the epidermis and dermis of the skin, and in the subcutaneous area the hard mass of fatty substances surrounded by proteins And the accumulation of body fluids. As a result, the skin has an "orange peel" appearance. Sebum particles most often cause problems in the thighs, buttocks, and upper arms, and are less common in the outer limbs, back, trunk, and center of the corpus callosum, and on the face and neck. It is usually not noticeable on the hands and feet. Sebum particles are often associated with obesity, but they also appear on the skin of individuals of normal or near-normal weight. It is more common in women than in men, and it is more common in Caucasians than in darker-skinned individuals. Due to the serious damage to the appearance of individuals, the skin granules have far-reaching psychological effects, hurt the self-esteem of the affected individuals, and are not conducive to the healthy psychological development of young men and women. Therefore, there is a great need for effective treatment of sebum particles. Known methods for treating sebum granules include local mechanical action. The local scale of the paper is generally the standard Chinese national standard (ΓΝ5) Λ4 size (210X297 gong) (please read the note on the back before filling in this page) * 1T ^ Printed by the Central Standards Bureau Shoulder Workers Consumer Cooperatives 5 45 0 9 a? __B7 ............... 5. Description of the Invention (3) Caffeine I Theophylline and other xanthines appear to be effective as diuretics and to promote fat metabolism at high concentrations. Aminophylline, currently a well-known active ingredient of thigh cream or thigh smoothing cream, seems to be effective as a strong diuretic to promote lymphatic drainage, but has been reported to have significant toxic side effects (See Merck Index, 11th edition, Merck &amp; Co. Inc. 1989 Monograph No. 477). These agents do not take into account structural defects in the skin and blood vessels. U.S. Patent No. 5,030,451 to Trebosc et al. Describes some cosmetic compositions containing an improved caffeine derivative as an active agent. According to Trebosc et al., Column 9, lines 15-20, the disclosed formula has "good and long-lasting 'fat-breaking properties'" and thus has proven very effective in slimming programs and treating sebum particles. &Quot; However, No valid data has been reported. In column 1, lines 61-65 &gt; Trebosc et al. Taught the faster rate of subcutaneous penetration and confirmed the superiority of these agents in treating sebum particles. Mausner US Patent No. 5 No. 21,759 refers to the use of methylsilanol theophylline acetate alginate and methylsilanol mannuronic acid for anti-sebum granules. Without descriptive disclosure, the effect of such substances is assumed to be Equal to diuretics. One disadvantage of marketing stimulant compositions (containing caffeine, aminophylline or related agents as active ingredients) for the treatment of sebum granules is that medication problems will prevent them from being included in pharmacies Ready-to-sell cosmetic composition. Long-term repeated use may cause harmful side effects, and government regulations will restrict marketing. Another disadvantage is that this kind of medicine _____ _ 6 & q uot;. _ This paper size applies to Chinese National Standards _ (CNS) M specifications (2ΙΟχ: 297 cm) (Please read the notes on the back before filling this page), 1Τ 4 5 45 0 9 A7 B7 Llti Warp Ministry of Health, Central Bureau, Prospective Staff, Consumer Cooperatives, Printing Co., Ltd. V. Invention Description (The agent does not take into account the structural problems of skin and vascular defects. Scrub particles mechanical action, remove the outer layer of treatment, smooth the treatment surface tt and stimulate treatment update, but failed to Promote lymphatic drainage, long-term microcirculation degradation or fat metabolism. Frosted particles are hard particles, usually suspended cream or glue, which are rubbed or massaged to achieve mechanical exfoliation. The particles are usually polyethylene balls However, natural particles such as crushed peaches or apricot kernels have also been used. The disadvantage of these products is that it is difficult to control allergies. Topical retinoids, such as US Patent No. 5,051,449 to Kligman, can have Limit the improvement of sebum granules. Kligman has published a qualitative report comparing the efficacy of a topical retinoic acid formula with an unnamed non-medical cream after more than 6 months Efficacy described includes skin thickening, increased number of new blood vessels, and measurable moderate to significant improvement using pinch test (column 6, lines 50-61). No quantitative data were provided Therefore, the skilled artisan cannot determine the value of Kligman's sebum treatment. Many people hope and expect that sebum treatment will be more effective than moderate improvement after 6 months of treatment. The concentration of retinoic acid administered must be limited To avoid allergies (see column 2 of Kligman, lines 59-60), it is not possible to achieve sufficient efficacy by increasing the dose • The retinoic acid treatment method does not provide a long-term treatment that is satisfactory for sebum particles, and more Effective topical treatment. Contrary to Kligman's unfounded induction, my quantitative clinical research found that after 3 months of daily treatment, retinoic acid did not cause significant skin thickening. Therefore, there is a need for an easy-to-apply sebum treatment that provides structural improvement in a reasonable amount of time. The size of this paper is Shizhou China. ((::?) / \ 4 size (210 &gt;: 297 feet) (Please read the notes on the back before filling this page), 1T A7 B7 J6 45 Ο 9 V. Description of the Invention (The present invention, as applied for a patent, is intended to provide a treatment method. It solves the problem of providing an easy-to-apply topical sebum granule treatment method that can be marketed to consumers more effectively than previously obtained methods, and It can cause obvious structural improvement in a reasonable time. The present invention also solves the problem of providing a local sebum granule treatment method that can produce gradual and structural improvement when it is continuously used for a long time, and the preferred embodiment promotes the body to suffer The skin of the affected area of sebaceous granules is obviously thickened and the tissue is strengthened, the thigh and thigh circumference are reduced, and the microcirculation blood flow is increased. The present invention solves the above problems by providing a sebum granule treatment method, which is applied to the skin affected by sebaceous granules. The tissue destroys the water barrier properties of the skin in this area for a long time, which is enough to stimulate the renewal of the treatment and the regeneration of blood vessels to achieve enhanced effects. The barrier is difficult. Of course, this method of destruction cannot be strong enough to damage the sensitive dermis layer of the skin, or cause pain or significant allergies. However, in order to obtain the efficacy of the present invention, the treatment should provide a long-lasting effect of destroying the barrier, Not temporary effects. Because the normal function of the barrier is necessary for survival, destroying the barrier will cause a natural response to quickly repair the barrier. In more detail, within a few weeks of extended treatment, such as 8 weeks or more The barrier effect is continuously damaged and the increase in water loss penetrating the epidermis can be used to monitor the barrier effect. TEWL was measured after 12 weeks of treatment, and at least 8 hours after the last treatment, known sebum particles other than retinoids were found Therapeutic methods have very little sustained effect on the barrier effect, some seem to reduce TEWL. Retinoic acid, a peeling agent, and at least another exfoliating agent, only show TEWL at 12 weeks. This paper is scaled to Chinese national standards. ((: NS) Λ4 Specification UIOX 297) (Please read the notes on the back before filling out this page) '1Τ Printed by Consumers Cooperatives A7 B7 Fifth Ministry of Economic Affairs Central Cotton Standards Bureau Consumer Cooperatives Cooperatives M 464509, Description of Invention (8) Skin moisture loss. Generally this treatment is applied once or twice a day. Many new sebum granule treatment methods Various local mechanical treatments for the skin, such as scrubs, roughening or extraction or solvent extraction treatments, both treatment methods are applied violently or aggressively to increase TEWL by 100% or more as described above and maintain it for a long time. However, preferred methods of treatment include a chemical composition that can be applied topically, preferably in the form of a softener or cream, and that maintains an increased level of TEWL at a frequency of no more than one or two applications per day. The urgency of the method of treatment of the present invention must be controlled so that it can be accepted over a period of weeks or months without causing severe or painful allergies, redness, peeling or excessive discomfort. However, many people can tolerate the short-term appearance of these symptoms. Another aspect of the present invention provides a sebum granule composition comprising a TEWL increasing agent capable of increasing TEWL immediately or short-term, and a barrier-damaging agent which acts to maintain the increased TEWL level. Preferably, the composition also includes a skin lipid inhibitor, to prevent premature reconstruction of the water barrier and enhance the therapeutic effect of the composition on the sebum particles. In a preferred embodiment of this aspect of the invention, the TEWlJf additive is a cosmetically compatible hydroxycarboxylic acid with a reduced pH, preferably has the properties of a peeling agent, and is at least moderately soluble in water or hydrogenated alcohol Enables inclusion in a cosmetic composition. Such acids include alpha-hydroxycarboxylic acids, especially such as lactic acid and glycolic acid, and other hydroxycarboxylic acids, such as 2-hydroxycarboxylic acid, especially salicylic acid. The effectiveness of these acids seems to be related to their ability to lower the skin's intercellular fluids. The acid used and its concentration are chosen to achieve the desired increase in TEWL without causing excessive hypersensitivity. (Please read the notes on the back before filling this page) Order-11-Correction too A 3 days | 4 6 4 5 0 9 This year a H A5 Supplement 90. 7. 20 B5 IV. Abstract of Chinese Invention (Invention of Invention Name: The pharmaceutical composition used to improve the condition of a sebum granule shows a new topical sebum granule treatment by structural comparison in the thigh area affected by sebum granules, followed by structural improvements, including thickening of skin, Thigh formation and thigh contraction. The disclosed treatment method disintegrates the wall of Pillu water and increases the water loss through the epidermis (TEWL) for long periods of time or months, and includes mechanical or solvent effects such as Band analysis or acetone rinsing. A better treatment method uses a cream, which contains active ingredients such as lactic acid to increase TEWL *-a retinoid * preferably vitamin A palmitate to break down the establishment and extension of the barrier The increase of TEWL, and a kind of cerebroside to inhibit the synthesis of lipids and strengthen the increase of TEWL. Diuretics, for the immediate progress of beauty treatment, anti-allergic agents and antioxidants to control the allergic reaction, are other components that can be added. Ying Zhang Summary of the invention Title of the invention: a pharmaceutical composition for ameliorating a cellulite condition Printed by the Shellfish Consumer Cooperative of Zhongli Bureau of the Ministry of Tao «. --------- I l Install I (Please read the notes on the back before filling (Each page on this page) IT line New topically applied treatments for cellulite are shown by ^ comparative data to effect structural improvements in cellulite-afflicted thigh area tissues including skinthickening, thigh-firming and thigh-reduction. The disclosed treatments disrupt the skints water barrier and elevate trans-epideriaal water loss (TEWL) for extended periods of weeks or months and include methods of mechanical; or solvent action, for example, tape stripping, or acetone-washes .Preferred treatments use creams with active ingredients such as lactic acid to elevate TEWL, a retinoid ,! preferably vitamin A palmitate to disrupt barrier rebuildingj and prolong elevation of TEWL levels, and a cerebroside to 丨 inhibit lipid synthesis and intensify. The TEWL elevation. Diuretics, for immediate esthetic improvements; anti-irritants and anti-oxidants for irritation control are optional ingredients, the paper ft scale uses the national ladder (CNS) A4 wash grid (2 丨 0X 297 mm) 5 4 6 〇 # 正 年月EI added 9〇H〇09 〇5 4 B 4 8888 ABCD Printed by the Ministry of Economic Affairs Bureau of the Ministry of Economic Affairs and Consumer Cooperatives 6. Application for Patent Scope No. 84108866 Patent Application Amendment of Patent Scope Amendment Date: 30 years 7. Month 1. A pharmaceutical composition for improving the condition of sebum granules, which is provided by continuous topical application to the skin area on tissues affected by sebum granules to cause long-term high-volume water loss through the epidermis for a period from 8 to 8 From week to until the desired improvement of sebum granules, the composition contains, based on the weight of the composition: a)-a ratio of 1 to 15% of a cosmetically compatible hydroxycarboxylic acid that reduces the positive value to increase Loss of water through the epidermis (TEWL); and b)-one of retinoid cell regeneration / differentiation modulators at a ratio of 0.005 to about 6.0%. 2. The pharmaceutical composition according to item 1 of the patent application, wherein the TEWL is increased by at least 100% after 8 weeks of sustained application. 3. For example, if you apply for a pharmaceutical composition in the scope of the first item of the patent, the performance application of the composition is to be continued for another 4 weeks "4. If you apply for a pharmaceutical composition in the scope of the first item of the patent, the composition is effective Increase TEWL by at least 100%, and its application period is from at least 8 weeks to 26 weeks. 5. The pharmaceutical composition according to item 1 of the patent application scope, further comprising: c) a cerebroside barrier repair inhibitor at a ratio of 0.01 to 5% to prevent the repair of the skin water barrier. 6. For example, the pharmaceutical composition in the scope of application for patent No. 5 wherein the composition is in accordance with the national standard of the paper (CNS M4 specification (2 丨 0 X 297 mm)) ι ^ ϋ ml In, ^^ ^^ 1---n ^ i i4n 1 ^ 1 ^ h. (Please read the precautions on the back before filling in this page)
TW84108866A 1994-08-26 1995-08-25 A pharmaceutical composition for ameliorating a cellulite condition TW464509B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/296,513 US5587396A (en) 1994-08-26 1994-08-26 Method of ameliorating cellulite by disrupting the barrier function of the stratum corneum

Publications (1)

Publication Number Publication Date
TW464509B true TW464509B (en) 2001-11-21

Family

ID=23142328

Family Applications (1)

Application Number Title Priority Date Filing Date
TW84108866A TW464509B (en) 1994-08-26 1995-08-25 A pharmaceutical composition for ameliorating a cellulite condition

Country Status (1)

Country Link
TW (1) TW464509B (en)

Similar Documents

Publication Publication Date Title
US5587396A (en) Method of ameliorating cellulite by disrupting the barrier function of the stratum corneum
TW537900B (en) A skin treatment comprising repeated topical application to structurally deteriorated skin of a skin water-vapor barrier disruption treatment effective to provide chronic disruption of the aged skin&#39;s water-vapor barrier said chronic disruption being
Rawlings et al. Moisturizer technology versus clinical performance
Mohiuddin Skin care creams: formulation and use
Zhai et al. Moisturizers in preventing irritant contact dermatitis: an overview.
EP0996418B1 (en) Dermatological compositions
JPH02218602A (en) Senile skin-treating composition
US20050182076A1 (en) Transdermal penetration system and treatment for cellulite
JP2012508267A (en) Compounds useful for the treatment of cellulite
JP2005046133A (en) Health food containing hyaluronic acid and dermatan sulfate
AU696398B2 (en) Cosmetic composition containing hydroxy alkanoate derivatives
JP4398641B2 (en) Hypoallergenic and non-irritating skin care preparations
CA2586308A1 (en) Methods for peeling skin
WO2017100873A1 (en) Cosmetic composition and use thereof
JP6584588B2 (en) Compositions and methods for the treatment of cellulite
TW464509B (en) A pharmaceutical composition for ameliorating a cellulite condition
EP0866693B1 (en) Topically applied, structural cellulite treatments
JP2013500317A (en) Use of isoleucine N-hexadecanoyl as a “volume increase” and / or “swelling” agent for human skin
AU722070B2 (en) Topically applied, structural cellulite treatments
JP4488933B2 (en) Wrinkle improving agent and external composition for skin
JPH09255546A (en) Skin preparation for external use
Ainurofiq et al. Characterization and application of moisturizer in skin treatment: A review: Moisturizer in Skin Treatment
Somwanshi et al. Cosmetic Science
JP2004168725A (en) External aqueous composition for skin
EP1363593A1 (en) Free nicotine based cosmetic composition and uses thereof

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees